Nabeel Nabulsi, PhD
Research & Publications
Biography
News
Research Summary
My interests in PET embrace both Chemistry and Imaging
Extensive Research Description
As a radiochemist, I find rewarding the development of facile
synthetic methodologies for the preparation of radiopharmaceuticals
which incorporate the short half-life C-11 and F-18 radionuclides that
are frequently employed for PET imaging. In particular, synthesis of
C-11 radiopharmaceuticals is very challenging in that it generally has
to be accomplished inside 60 minutes in order to possess adequate
radioactivity for PET imaging.
Improving overall binding properties of existing radioligands and the
development of new ligands comprise my imaging interest in the areas of
CNS and oncology. For CNS, I am interested in developing
radiopharmaceuticals that can be employed for early diagnosis of
Alzheimer and Parkinson diseases and which can lead to development of
better treatments. Another interesting area, FAAH (fatty acid amide
hydrolase) has emerged as a novel therapeutic target for a range of
clinical disorders. It is a membrane-bound intracellular serine
hydrolase that is responsible for AEA (Anandamide, an endogenous
cannabinoid) metabolism. Indeed, FAAH has been targeted as biomarker of
AEA which is known to modulate several physiological processes in both
peripheral and nervous system. FAAH inactivation produces proactive
subset of behavioral effects similar to that observed for direct CB1
agonists, but without inducing analogous side-effects. To date, all
evidence suggests that compounds which increase the tone of AEA, whether
blocking its transport or inhibiting its metabolism, are
therapeutically valuable for treatment. Accordingly imaging FAAH should
accelerate validation of FAAH inhibitors as therapeutic targets.
Small-molecule radiotracers not only would provide valuable research
tools for further understanding of this and other therapeutic targets,
but also allows fast validation of efficacy and selectivity of potential
drug inhibitors as well. The potential disorders which can benefit from
targeted enhancement of AEA include analgesic, anti tumor and neuroprotection.
Regarding oncology, there is a dire need for radiotracers which are
capable of early detection of pancreatic cancer. It is the second most
common gastrointestinal malignancy in the USA. Meanwhile, peptide
transporters are important drug delivery targets and growing number of
studies have been reported on regulation of their transport capacity.
Tumor cells have been shown to up-regulate the expression of the peptide
transporter type PepT1, and high levels of this transporter have been
found in variety of cancer cells, including pancreatic. Thus, increased
expression of PepT1 in the cellular membrane of cancer cells has been
investigated as a possible target for delivery of peptidomimetic
anti-cancer drugs as well as prodrugs. Bestatin, a leukotriene A4
hydrolase inhibitor, is among the peptidomimetic PepT1 substrates which
have been shown to have anticancer activity towards non-lymphocytic
leukemia as well as pancreatic adenocarcinoma. In this regard, I am
interested in developing radiotracers that are substrates of the peptide
transporter PepT1 for imaging pancreatic cancer. Alternatively,
inhibition of PepT1 activity has also been suggested as a novel
chemotherapy approach. With this in mind, radiotracers that are
substrates for PepT1 should also facilitate the development of PepT1
inhibitors.
Coauthors
Research Image
Selected Publications
- The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-JToyonaga T, Khattar N, Wu Y, Lu Y, Naganawa M, Gallezot J, Matuskey D, Mecca A, Pittman B, Dias M, Nabulsi N, Finnema S, Chen M, Arnsten A, Radhakrishnan R, Skosnik P, D’Souza D, Esterlis I, Huang Y, van Dyck C, Carson R. The regional pattern of age-related synaptic loss in the human brain differs from gray matter volume loss: in vivo PET measurement with [11C]UCB-J. European Journal Of Nuclear Medicine And Molecular Imaging 2023, 51: 1012-1022. PMID: 37955791, DOI: 10.1007/s00259-023-06487-8.
- O-57 Synthesis and translational evaluation of three novel PARP PET tracers in nonhuman primates and rodent glioma brain tumor model with intact blood-brain barrierTong J, Takuya T, Thomas M, Chen M, Holden D, Kurpiewski S, Katz S, Chen B, Mennie W, Wenn M, Kapinos M, Zhang L, Felchner Z, Gao H, Labaree D, Fowles K, Ropchan J, Nabulsi N, De Feyter H, Carson R, Huang H, Cai J. O-57 Synthesis and translational evaluation of three novel PARP PET tracers in nonhuman primates and rodent glioma brain tumor model with intact blood-brain barrier. Nuclear Medicine And Biology 2023, 126: 108453. DOI: 10.1016/j.nucmedbio.2023.108453.
- Evaluating infusion methods and simplified quantification of synaptic density in vivo with [11C]UCB-J and [18F]SynVesT-1 PETAsch R, Naganawa M, Nabulsi N, Huan Y, Esterlis I, Carson R. Evaluating infusion methods and simplified quantification of synaptic density in vivo with [11C]UCB-J and [18F]SynVesT-1 PET. Cerebrovascular And Brain Metabolism Reviews 2023, 43: 2120-2129. PMID: 37669455, PMCID: PMC10925870, DOI: 10.1177/0271678x231200423.
- Assessment of Gray Matter Microstructure and Synaptic Density in Alzheimer's Disease: A Multimodal Imaging Study With DTI and SV2A PETSilva-Rudberg J, Salardini E, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Varma P, Toyonaga T, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of Gray Matter Microstructure and Synaptic Density in Alzheimer's Disease: A Multimodal Imaging Study With DTI and SV2A PET. American Journal Of Geriatric Psychiatry 2023, 32: 17-28. PMID: 37673749, PMCID: PMC10840732, DOI: 10.1016/j.jagp.2023.08.002.
- Imaging the brain’s immune response to alcohol with [11C]PBR28 TSPO Positron Emission TomographyRaval N, Angarita G, Matuskey D, Miller R, Drake L, Kapinos M, Nabulsi N, Huang Y, Carson R, O’Malley S, Cosgrove K, Hillmer A. Imaging the brain’s immune response to alcohol with [11C]PBR28 TSPO Positron Emission Tomography. Molecular Psychiatry 2023, 28: 3384-3390. PMID: 37532797, PMCID: PMC10743097, DOI: 10.1038/s41380-023-02198-6.
- Principal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer’s diseaseO'Dell R, Higgins-Chen A, Gupta D, Chen M, Naganawa M, Toyonaga T, Lu Y, Ni G, Chupak A, Zhao W, Salardini E, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C, Mecca A. Principal component analysis of synaptic density measured with [11C]UCB-J PET in early Alzheimer’s disease. NeuroImage Clinical 2023, 39: 103457. PMID: 37422964, PMCID: PMC10338149, DOI: 10.1016/j.nicl.2023.103457.
- 553. Preliminary Evidence for an Elevated Neuroinflammatory Signal in Opioid Use Disorder: Findings From a PET TSPO Imaging StudyWoodcock E, Angarita G, Matuskey D, Ropchan J, Nabulsi N, Huang Y, Hillmer A, Carson R, Malison R, Cosgrove K. 553. Preliminary Evidence for an Elevated Neuroinflammatory Signal in Opioid Use Disorder: Findings From a PET TSPO Imaging Study. Biological Psychiatry 2023, 93: s317-s318. DOI: 10.1016/j.biopsych.2023.02.793.
- 573. Distinct Pattern of Synaptic Loss in Parkinson’s Disease DepressionYang Y, Naganawa M, Honhar P, Tinaz S, Dias M, Henry S, Ropcham J, Comley R, Nabulsi N, Huang Y, Carson R, Finnema S, Matuskey D, Holmes S. 573. Distinct Pattern of Synaptic Loss in Parkinson’s Disease Depression. Biological Psychiatry 2023, 93: s326. DOI: 10.1016/j.biopsych.2023.02.813.
- Investigating synaptic changes in Essential Tremor with PET Imaging (P7-11.005)Yang Y, Naganawa M, Hernadenz N, Nguyen N, Nabulsi N, Huang Y, Carson R, Matuskey D, Louis E. Investigating synaptic changes in Essential Tremor with PET Imaging (P7-11.005). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000202645.
- Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primatesChen B, Ojha D, Toyonaga T, Tong J, Pracitto R, Thomas M, Liu M, Kapinos M, Zhang L, Zheng M, Holden D, Fowles K, Ropchan J, Nabulsi N, De Feyter H, Carson R, Huang Y, Cai Z. Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primates. European Journal Of Nuclear Medicine And Molecular Imaging 2023, 50: 2081-2099. PMID: 36849748, DOI: 10.1007/s00259-023-06162-y.
- Investigating CNS distribution of PF‐05212377, a P‐glycoprotein substrate, by translation of 5‐HT6 receptor occupancy from non‐human primates to humansSawant‐Basak A, Chen L, Lockwood P, Boyden T, Doran A, Mancuso J, Zasadny K, McCarthy T, Morris E, Carson R, Esterlis I, Huang Y, Nabulsi N, Planeta B, Fullerton T. Investigating CNS distribution of PF‐05212377, a P‐glycoprotein substrate, by translation of 5‐HT6 receptor occupancy from non‐human primates to humans. Biopharmaceutics & Drug Disposition 2023, 44: 48-59. PMID: 36825693, DOI: 10.1002/bdd.2351.
- Serotonin transporter availability in physically aggressive personality disordered patients: associations with trait and state aggression, and response to fluoxetineRosell D, Slifstein M, Thompson J, Xu X, Perez-Rodriguez M, McClure M, Hazlett E, New A, Nabulsi N, Huang Y, Carson R, Siever L, Abi-Dargham A, Koenigsberg H. Serotonin transporter availability in physically aggressive personality disordered patients: associations with trait and state aggression, and response to fluoxetine. Psychopharmacology 2023, 240: 361-371. PMID: 36640190, DOI: 10.1007/s00213-022-06306-2.
- Assessment of gray matter microstructure and synaptic density in Alzheimer’s Disease: a multimodal imaging study with DWI and SV2A PETSalardini E, Silva‐Rudberg J, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of gray matter microstructure and synaptic density in Alzheimer’s Disease: a multimodal imaging study with DWI and SV2A PET. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.065064.
- Assessment of gray matter microstructure and synaptic density in Alzheimer's Disease: a multimodal imaging study with DWI and SV2A PETSalardini E, Silva‐Rudberg J, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of gray matter microstructure and synaptic density in Alzheimer's Disease: a multimodal imaging study with DWI and SV2A PET. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.065162.
- Association of synaptic density and glucose metabolism with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB‐J and [18F]FDGO'Dell R, Mecca A, Waszak J, Sharp E, Chen M, Naganawa M, Toyonaga T, Lu Y, Chupak A, Cooper E, Lam J, Miller A, Waldner E, Weibley H, Zhao Y, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C. Association of synaptic density and glucose metabolism with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB‐J and [18F]FDG. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.062595.
- Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adultsMatuskey D, Gallezot J, Nabulsi N, Henry S, Torres K, Dias M, Angarita G, Huang Y, Shoaf S, Carson R, Mehrotra S. Neurotransmitter transporter occupancy following administration of centanafadine sustained-release tablets: A phase 1 study in healthy male adults. Journal Of Psychopharmacology 2022, 37: 164-171. PMID: 36515395, PMCID: PMC9912308, DOI: 10.1177/02698811221140008.
- Differences in quantification of the metabotropic glutamate receptor 5 (mGluR5) across bipolar disorder and major depressive disorderHolmes S, Asch R, Davis M, DellaGioia N, Pashankar N, Gallezot J, Nabulsi N, Matuskey D, Sanacora G, Carson R, Blumberg H, Esterlis I. Differences in quantification of the metabotropic glutamate receptor 5 (mGluR5) across bipolar disorder and major depressive disorder. Biological Psychiatry 2022 PMID: 36764853, DOI: 10.1016/j.biopsych.2022.10.018.
- Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2ANaganawa M, Gallezot J, Finnema S, Maguire R, Mercier J, Nabulsi N, Kervyn S, Henry S, Nicolas J, Huang Y, Chen M, Hannestad J, Klitgaard H, Stockis A, Carson R. Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A. EJNMMI Research 2022, 12: 71. PMID: 36346513, PMCID: PMC9643320, DOI: 10.1186/s13550-022-00944-5.
- RF12 | PSUN106 Quantifying Liver and Brain Levels of 11β-hydroxysteroid Dehydrogenase Type 1 in Obesity Using Positron Emission Tomography ImagingBini J, Gallezot J, Li S, Lim K, Emery P, Kapinos M, Ropchan J, Nabulsi N, Jastreboff A, Huang Y, Carson R. RF12 | PSUN106 Quantifying Liver and Brain Levels of 11β-hydroxysteroid Dehydrogenase Type 1 in Obesity Using Positron Emission Tomography Imaging. Journal Of The Endocrine Society 2022, 6: a29-a30. PMCID: PMC9624872, DOI: 10.1210/jendso/bvac150.062.
- Age, gender and body-mass-index relationships with in vivo CB1 receptor availability in healthy humans measured with [11C]OMAR PETRadhakrishnan R, Worhunsky PD, Zheng MQ, Najafzadeh S, Gallezot JD, Planeta B, Henry S, Nabulsi N, Ranganathan M, Skosnik PD, Pittman B, Cyril D'Souza D, Carson RE, Huang Y, Potenza MN, Matuskey D. Age, gender and body-mass-index relationships with in vivo CB1 receptor availability in healthy humans measured with [11C]OMAR PET. NeuroImage 2022, 264: 119674. PMID: 36243269, DOI: 10.1016/j.neuroimage.2022.119674.
- First-in-human evaluation of 18F-BMS-986327 as a novel PET tracer to assess lysophosphatidic acid receptor 1 (LPA1) target engagement in the lungSmith R, Donnelly D, Gallezot J, Lu Y, Murphy B, Cheng P, Kim J, Charles E, Du S, Holden D, Najafzadeh S, Gao H, Kapinos M, Ropchan J, Nabulsi N, Huang H, Fischer A, Carson R. First-in-human evaluation of 18F-BMS-986327 as a novel PET tracer to assess lysophosphatidic acid receptor 1 (LPA1) target engagement in the lung. 2022, 1164. DOI: 10.1183/13993003.congress-2022.1164.
- Systemic inflammation enhances stimulant-induced striatal dopamine elevation in tobacco smokersZakiniaeiz Y, Hoye J, Ryan Petrulli J, LeVasseur B, Stanley G, Gao H, Najafzadeh S, Ropchan J, Nabulsi N, Huang Y, Chen MK, Matuskey D, Barron DS, Kelmendi B, Fulbright RK, Hampson M, Cosgrove KP, Morris ED. Systemic inflammation enhances stimulant-induced striatal dopamine elevation in tobacco smokers. Brain Behavior And Immunity 2022, 106: 262-269. PMID: 36058419, PMCID: PMC10097458, DOI: 10.1016/j.bbi.2022.08.016.
- Differences in the association between kappa opioid receptors and pain among Black and White adults with alcohol use disordersde Laat B, Nabulsi N, Huang Y, O'Malley SS, Morris ED, Krishnan‐Sarin S. Differences in the association between kappa opioid receptors and pain among Black and White adults with alcohol use disorders. Alcohol Clinical And Experimental Research 2022, 46: 1348-1357. PMID: 35633151, DOI: 10.1111/acer.14879.
- Imaging the fetal nonhuman primate brain with SV2A positron emission tomography (PET)Rossano S, Toyonaga T, Berg E, Lorence I, Fowles K, Nabulsi N, Ropchan J, Li S, Ye Y, Felchner Z, Kukis D, Huang Y, Benveniste H, Tarantal AF, Groman S, Carson RE. Imaging the fetal nonhuman primate brain with SV2A positron emission tomography (PET). European Journal Of Nuclear Medicine And Molecular Imaging 2022, 49: 3679-3691. PMID: 35633376, PMCID: PMC9826644, DOI: 10.1007/s00259-022-05825-6.
- Feasibility of imaging synaptic density in the human spinal cord using [11C]UCB-J PETRossano S, Toyonaga T, Bini J, Nabulsi N, Ropchan J, Cai Z, Huang Y, Carson RE. Feasibility of imaging synaptic density in the human spinal cord using [11C]UCB-J PET. EJNMMI Physics 2022, 9: 32. PMID: 35503134, PMCID: PMC9065222, DOI: 10.1186/s40658-022-00464-0.
- P-303 Synthesis and preclinical evaluation of PD-L1 PET tracer [18F]FDHPA in miceTong J, Chen B, Alluri S, Gu J, Zheng M, Zheng C, Felchner Z, Gao H, Zhang L, Kapinos M, Labaree D, Ropchan J, Nabulsi N, Marquez-Nostra B, Carson R, Huang Y, Cai Z. P-303 Synthesis and preclinical evaluation of PD-L1 PET tracer [18F]FDHPA in mice. Nuclear Medicine And Biology 2022, 108: s214. DOI: 10.1016/s0969-8051(22)00439-5.
- P-304 The synthesis and bioevaluation of a novel and brain penetrable PARP1 tracer [18F]Pamiparib in rodents and nonhuman primatesTong J, Chen B, Gu J, Alluri S, Zheng M, Zheng C, Felchner Z, Gao H, Zhang L, Kapinos M, Labaree D, Ropchan J, Nabulsi N, Carson R, Huang Y, Cai Z. P-304 The synthesis and bioevaluation of a novel and brain penetrable PARP1 tracer [18F]Pamiparib in rodents and nonhuman primates. Nuclear Medicine And Biology 2022, 108: s214-s215. DOI: 10.1016/s0969-8051(22)00440-1.
- P95. Cortical Amyloid Burden is Associated With Basal Forebrain but Not Medial Temporal Lobe Atrophy in Adults at Varying APOE ɛ4 Risk for Alzheimer’s DiseaseKelly K, O'Dell R, Toyonaga T, Barcelos N, Gelernter J, Varma P, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. P95. Cortical Amyloid Burden is Associated With Basal Forebrain but Not Medial Temporal Lobe Atrophy in Adults at Varying APOE ɛ4 Risk for Alzheimer’s Disease. Biological Psychiatry 2022, 91: s125-s126. DOI: 10.1016/j.biopsych.2022.02.329.
- P204. Role of Kappa Opioid Receptor Availability in Borderline Personality Disorder and Suicidal Behavior: Preliminary Results From an in Vivo [11C]EKAP PET StudyDavis M, Wilson O, DeBonee S, Nabulsi N, Matuskey D, Esterlis I. P204. Role of Kappa Opioid Receptor Availability in Borderline Personality Disorder and Suicidal Behavior: Preliminary Results From an in Vivo [11C]EKAP PET Study. Biological Psychiatry 2022, 91: s169-s170. DOI: 10.1016/j.biopsych.2022.02.438.
- Assessment of gray matter microstructure and synaptic density in Alzheimer's disease: A multimodal imaging study with DWI and SV2A PETSilva-Rudberg J, Salardini E, O'Dell R, Chen M, Ra J, Georgelos J, Morehouse M, Melino K, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Assessment of gray matter microstructure and synaptic density in Alzheimer's disease: A multimodal imaging study with DWI and SV2A PET. American Journal Of Geriatric Psychiatry 2022, 30: s26. DOI: 10.1016/j.jagp.2022.01.303.
- The relationship between cortical amyloid burden and basal forebrain volume in adults at varying APOE ?4 risk for Alzheimer's diseaseKelly K, Toyonaga T, Zhao W, Barcelos N, Gelernter J, Varma P, Nabulsi N, Wyk B, Huang Y, Carson R, van Dyck C, Mecca A. The relationship between cortical amyloid burden and basal forebrain volume in adults at varying APOE ?4 risk for Alzheimer's disease. American Journal Of Geriatric Psychiatry 2022, 30: s25. DOI: 10.1016/j.jagp.2022.01.301.
- Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [11C]UCB‐JMecca AP, O'Dell RS, Sharp ES, Banks ER, Bartlett HH, Zhao W, Lipior S, Diepenbrock NG, Chen M, Naganawa M, Toyonaga T, Nabulsi NB, Wyk B, Arnsten AFT, Huang Y, Carson RE, van Dyck C. Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [11C]UCB‐J. Alzheimer's & Dementia 2022, 18: 2527-2536. PMID: 35174954, PMCID: PMC9381645, DOI: 10.1002/alz.12582.
- Imaging the effect of ketamine on synaptic density (SV2A) in the living brainHolmes SE, Finnema SJ, Naganawa M, DellaGioia N, Holden D, Fowles K, Davis M, Ropchan J, Emory P, Ye Y, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, Sanacora G, Krystal JH, Carson RE, Esterlis I. Imaging the effect of ketamine on synaptic density (SV2A) in the living brain. Molecular Psychiatry 2022, 27: 2273-2281. PMID: 35165397, PMCID: PMC9133063, DOI: 10.1038/s41380-022-01465-2.
- Nicotine Patch Alters Patterns of Cigarette Smoking-Induced Dopamine Release: Patterns Relate to Biomarkers Associated With Treatment ResponseZakiniaeiz Y, Liu H, Gao H, Najafzadeh S, Ropchan J, Nabulsi N, Huang Y, Matuskey D, Chen MK, Cosgrove KP, Morris ED. Nicotine Patch Alters Patterns of Cigarette Smoking-Induced Dopamine Release: Patterns Relate to Biomarkers Associated With Treatment Response. Nicotine & Tobacco Research 2022, 24: 1597-1606. PMID: 35100429, PMCID: PMC9575980, DOI: 10.1093/ntr/ntac026.
- Translational PET Imaging of Spinal Cord Injury with the Serotonin Transporter Tracer [11C]AFMFang H, Rossano S, Wang X, Nabulsi N, Kelley B, Fowles K, Ropchan J, Strittmatter SM, Carson RE, Huang Y. Translational PET Imaging of Spinal Cord Injury with the Serotonin Transporter Tracer [11C]AFM. Molecular Imaging And Biology 2022, 24: 560-569. PMID: 35020138, PMCID: PMC9550197, DOI: 10.1007/s11307-021-01698-7.
- Cerebrospinal fluid and brain PET measures of synaptic density glycoprotein 2A: Biomarkers of synaptic density in Alzheimer’s diseaseMecca A, Ashton N, Chen M, O'Dell R, Naganawa M, Toyonaga T, Zhao W, Nabulsi N, Brinkmalm A, Kvartsberg H, Schöll M, Arnsten A, Huang Y, Blennow K, Zetterberg H, Carson R, van Dyck C, Nilsson J. Cerebrospinal fluid and brain PET measures of synaptic density glycoprotein 2A: Biomarkers of synaptic density in Alzheimer’s disease. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.054831.
- Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: An exploratory 11C‐UCB‐J positron emission tomography study in humansAngarita GA, Worhunsky PD, Naganawa M, Toyonaga T, Nabulsi NB, Li C, Esterlis I, Skosnik PD, Radhakrishnan R, Pittman B, Gueorguieva R, Potenza MN, Finnema SJ, Huang Y, Carson RE, Malison RT. Lower prefrontal cortical synaptic vesicle binding in cocaine use disorder: An exploratory 11C‐UCB‐J positron emission tomography study in humans. Addiction Biology 2021, 27: e13123. PMID: 34852401, PMCID: PMC8891080, DOI: 10.1111/adb.13123.
- Synaptic density is associated with cognitive performance in Alzheimer’s disease: A PET imaging study with [11C]UCB‐Jvan Dyck C, Sharp E, O'Dell R, Banks E, Bartlett H, Chen M, Naganawa M, Toyonaga T, Harris J, Ni G, Zhao W, Nabulsi N, Wyk B, Huang Y, Arnsten A, Carson R, Mecca A. Synaptic density is associated with cognitive performance in Alzheimer’s disease: A PET imaging study with [11C]UCB‐J. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.054213.
- Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's diseaseMecca AP, Chen MK, O'Dell RS, Naganawa M, Toyonaga T, Godek TA, Harris JE, Bartlett HH, Zhao W, Banks ER, Ni GS, Rogers K, Gallezot JD, Ropchan J, Emery PR, Nabulsi NB, Vander Wyk BC, Arnsten AFT, Huang Y, Carson RE, van Dyck CH. Association of entorhinal cortical tau deposition and hippocampal synaptic density in older individuals with normal cognition and early Alzheimer's disease. Neurobiology Of Aging 2021, 111: 44-53. PMID: 34963063, PMCID: PMC8761170, DOI: 10.1016/j.neurobiolaging.2021.11.004.
- A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [18F]SDM-16Zheng C, Holden D, Zheng MQ, Pracitto R, Wilcox KC, Lindemann M, Felchner Z, Zhang L, Tong J, Fowles K, Finnema SJ, Nabulsi N, Carson RE, Huang Y, Cai Z. A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [18F]SDM-16. European Journal Of Nuclear Medicine And Molecular Imaging 2021, 49: 1482-1496. PMID: 34761284, PMCID: PMC8940841, DOI: 10.1007/s00259-021-05597-5.
- Imaging brain cortisol regulation in PTSD with a target for 11β-hydroxysteroid dehydrogenase type 1Bhatt S, Hillmer AT, Rusowicz A, Nabulsi N, Matuskey D, Angarita GA, Najafzadeh S, Kapinos M, Southwick SM, Krystal JH, Carson RE, Huang Y, Cosgrove KP. Imaging brain cortisol regulation in PTSD with a target for 11β-hydroxysteroid dehydrogenase type 1. Journal Of Clinical Investigation 2021, 131: e150452. PMID: 34651587, PMCID: PMC8516462, DOI: 10.1172/jci150452.
- Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer 11C-TASP699Naganawa M, Nabulsi NB, Matuskey D, Henry S, Ropchan J, Lin SF, Gao H, Pracitto R, Labaree D, Zhang MR, Suhara T, Nishino I, Sabia H, Ozaki S, Huang Y, Carson RE. Imaging Pituitary Vasopressin 1B Receptor in Humans with the PET Radiotracer 11C-TASP699. Journal Of Nuclear Medicine 2021, 63: 609-614. PMID: 34385336, DOI: 10.2967/jnumed.121.262430.
- Assessment of transient dopamine responses to smoked cannabisCalakos KC, Liu H, Lu Y, Anderson JM, Matuskey D, Nabulsi N, Ye Y, Skosnik PD, D'Souza DC, Morris ED, Cosgrove KP, Hillmer AT. Assessment of transient dopamine responses to smoked cannabis. Drug And Alcohol Dependence 2021, 227: 108920. PMID: 34399137, PMCID: PMC8464527, DOI: 10.1016/j.drugalcdep.2021.108920.
- In vivo evidence of lower synaptic vesicle density in schizophreniaRadhakrishnan R, Skosnik PD, Ranganathan M, Naganawa M, Toyonaga T, Finnema S, Hillmer AT, Esterlis I, Huang Y, Nabulsi N, Carson RE, D’Souza D. In vivo evidence of lower synaptic vesicle density in schizophrenia. Molecular Psychiatry 2021, 26: 7690-7698. PMID: 34135473, DOI: 10.1038/s41380-021-01184-0.
- Effect of age on brain metabotropic glutamate receptor subtype 5 measured with [18F]FPEB PETMecca AP, Rogers K, Jacobs Z, McDonald JW, Michalak HR, DellaGioia N, Zhao W, Hillmer AT, Nabulsi N, Lim K, Ropchan J, Huang Y, Matuskey D, Esterlis I, Carson RE, van Dyck CH. Effect of age on brain metabotropic glutamate receptor subtype 5 measured with [18F]FPEB PET. NeuroImage 2021, 238: 118217. PMID: 34052464, PMCID: PMC8378132, DOI: 10.1016/j.neuroimage.2021.118217.
- Synaptic Loss is Associated With Cognitive Impairment in Early Alzheimer’s Disease: A PET Imaging Study With [11C]UCB-JO'Dell R, Mecca A, Sharp E, Banks E, Bartlett H, Chen M, Naganawa M, Toyonaga T, Harris J, Ni G, Zhao W, Nabulsi N, Wyk B, Huang Y, Carson R, Arnsten A, van Dyck C. Synaptic Loss is Associated With Cognitive Impairment in Early Alzheimer’s Disease: A PET Imaging Study With [11C]UCB-J. Biological Psychiatry 2021, 89: s107-s108. DOI: 10.1016/j.biopsych.2021.02.276.
- Vitamin D Modulation of Midbrain Dopamine Function: A 11C-PHNO PET Study in Healthy HumansFlores J, Worhunsky P, Costeines J, Driesen N, Rowland M, Nabulsi N, Trink R, Pittman B, Huang H, DiLeone R, Potenza M, Carson R, Angarita G, Malison R. Vitamin D Modulation of Midbrain Dopamine Function: A 11C-PHNO PET Study in Healthy Humans. Biological Psychiatry 2021, 89: s253. DOI: 10.1016/j.biopsych.2021.02.634.
- Morphine Induces a Neuroimmune Response in Healthy Volunteers: Implications for Opioid Use DisorderWoodcock E, Angarita G, Matuskey D, Ropchan J, Nabulsi N, Huang Y, Hillmer A, Carson R, Cosgrove K. Morphine Induces a Neuroimmune Response in Healthy Volunteers: Implications for Opioid Use Disorder. Biological Psychiatry 2021, 89: s252-s253. DOI: 10.1016/j.biopsych.2021.02.632.
- Imaging the Effect of Ketamine on Synaptic (SV2A) DensityHolmes S, Finnema S, Naganawa M, DellaGioia N, Holden D, Fowles K, Ropchan J, Emory P, Ye Y, Nabulsi N, Matuskey D, Angarita G, Duman R, Sanacora G, Krystal J, Carson R, Esterlis I. Imaging the Effect of Ketamine on Synaptic (SV2A) Density. Biological Psychiatry 2021, 89: s35. DOI: 10.1016/j.biopsych.2021.02.105.
- Evaluation of quantitative modeling methods in whole-body, dynamic [11C]-erlotinib PET.Petrulli JR, Zheng M, Huang Y, Nabulsi NB, Goldberg SB, Contessa JN, Morris ED. Evaluation of quantitative modeling methods in whole-body, dynamic [11C]-erlotinib PET. Am J Nucl Med Mol Imaging 2021, 11: 143-153. PMID: 34079641, PMCID: PMC8165727.
- Principal component analysis of synaptic density measured with [11C]UCB-J PET in Alzheimer's diseaseO'Dell R, Higgins-Chen A, Gupta D, Chen M, Naganawa M, Toyonaga T, Lu Y, Banks E, Bartlett H, Harris J, Zhao W, Nabulsi N, Wyk B, Huang Y, Arnsten A, Carson R, van Dyck C, Mecca A. Principal component analysis of synaptic density measured with [11C]UCB-J PET in Alzheimer's disease. American Journal Of Geriatric Psychiatry 2021, 29: s47-s48. DOI: 10.1016/j.jagp.2021.01.041.
- Synaptic density is associated with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB-JSharp E, O'Dell R, Banks E, Bartlett H, Chen M, Naganawa M, Toyonaga T, Harris J, Ni G, Zhao W, Nabulsi N, Wyk B, Huang Y, Arnsten A, Carson R, Mecca A, van Dyck C. Synaptic density is associated with cognitive performance in early Alzheimer's disease: a PET imaging study with [11C]UCB-J. American Journal Of Geriatric Psychiatry 2021, 29: s119-s120. DOI: 10.1016/j.jagp.2021.01.114.
- Association of Aß deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [11C]UCB-JO'Dell R, Mecca A, Chen M, Naganawa M, Toyonaga T, Lu Y, Godek T, Harris J, Bartlett H, Banks E, Kominek V, Zhao W, Nabulsi N, Ropchan J, Ye Y, Wyk B, Huang Y, Arnsten A, Carson R, van Dyck C. Association of Aß deposition and regional synaptic density in early Alzheimer's disease: a PET imaging study with [11C]UCB-J. American Journal Of Geriatric Psychiatry 2021, 29: s37-s40. DOI: 10.1016/j.jagp.2021.01.034.
- Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer’s disease: A tracer kinetic modeling studyChen MK, Mecca AP, Naganawa M, Gallezot JD, Toyonaga T, Mondal J, Finnema SJ, Lin SF, O’Dell R, McDonald JW, Michalak HR, Wyk B, Nabulsi NB, Huang Y, Arnsten AF, van Dyck CH, Carson RE. Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer’s disease: A tracer kinetic modeling study. Cerebrovascular And Brain Metabolism Reviews 2021, 41: 2395-2409. PMID: 33757318, PMCID: PMC8393289, DOI: 10.1177/0271678x211004312.
- PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human Brain.Smart K, Naganawa M, Baldassarri SR, Nabulsi N, Ropchan J, Najafzadeh S, Gao H, Navarro A, Barth V, Esterlis I, Cosgrove KP, Huang Y, Carson RE, Hillmer AT. PET Imaging Estimates of Regional Acetylcholine Concentration Variation in Living Human Brain. Cerebral Cortex 2021, 31: 2787-2798. PMID: 33442731, PMCID: PMC8355478, DOI: 10.1093/cercor/bhaa387.
- Dopamine D2/3 receptor availability in cocaine use disorder individuals with obesity as measured by [11C]PHNO PETMatuskey D, Angarita GA, Worhunsky P, Koohsari S, Gravel P, Pittman B, Gaiser EC, Gallezot JD, Nabulsi N, Huang Y, Carson RE, Potenza MN, Malison RT. Dopamine D2/3 receptor availability in cocaine use disorder individuals with obesity as measured by [11C]PHNO PET. Drug And Alcohol Dependence 2021, 220: 108514. PMID: 33454626, PMCID: PMC7889720, DOI: 10.1016/j.drugalcdep.2021.108514.
- Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2ALi S, Naganawa M, Pracitto R, Najafzadeh S, Holden D, Henry S, Matuskey D, Emery PR, Cai Z, Ropchan J, Nabulsi N, Carson RE, Huang Y. Assessment of test-retest reproducibility of [18F]SynVesT-1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A. European Journal Of Nuclear Medicine And Molecular Imaging 2021, 48: 1327-1338. PMID: 33416954, DOI: 10.1007/s00259-020-05149-3.
- Association of Aβ deposition and regional synaptic density in early Alzheimer’s disease: a PET imaging study with [11C]UCB-JO’Dell R, Mecca AP, Chen MK, Naganawa M, Toyonaga T, Lu Y, Godek TA, Harris JE, Bartlett HH, Banks ER, Kominek VL, Zhao W, Nabulsi NB, Ropchan J, Ye Y, Vander Wyk BC, Huang Y, Arnsten AFT, Carson RE, van Dyck CH. Association of Aβ deposition and regional synaptic density in early Alzheimer’s disease: a PET imaging study with [11C]UCB-J. Alzheimer's Research & Therapy 2021, 13: 11. PMID: 33402201, PMCID: PMC7786921, DOI: 10.1186/s13195-020-00742-y.
- Association between cerebral amyloid accumulation and synaptic density in Alzheimer’s disease: A multitracer PET studyO'Dell R, Mecca A, Chen M, Godek T, Harris J, Bartlett H, Banks E, Kominek V, Zhao W, Naganawa M, Toyonaga T, Lu Y, Nabulsi N, Ropchan J, Ye Y, Wyk B, Varma P, Arnsten A, Huang Y, Carson R, van Dyck C. Association between cerebral amyloid accumulation and synaptic density in Alzheimer’s disease: A multitracer PET study. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.043631.
- 11C‐PBR28 brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer’s diseaseSalardini A, Hillmer A, Mecca A, Hashemi‐Aghdam A, Laltoo E, Savoia S, O'Dell R, Harris J, Godek T, Nabulsi N, Lim K, Ropchan J, Huang Y, Cosgrove K, Carson R, Strittmatter S, van Dyck C. 11C‐PBR28 brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.043584.
- Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer’s diseaseMecca A, Ashton N, Chen M, O'Dell R, Naganawa M, Toyonaga T, Harris J, Bartlett H, Banks E, Kominek V, Nabulsi N, Najafzadeh S, Wyk B, Brinkmalm A, Kvartsberg H, Schöll M, Arnsten A, Huang Y, Blennow K, Zetterberg H, Carson R, van Dyck C. Association between cerebrospinal fluid biomarkers of neurodegeneration and PET measurements of synaptic density in Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.044211.
- PBR28 Brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer’s diseaseSalardini A, Hillmer A, Mecca A, Hashemi‐Aghdam A, Laltoo E, Savoia S, O'Dell R, Harris J, Godek T, Nabulsi N, Lim K, Ropchan J, Huang Y, Cosgrove K, Carson R, Strittmatter S, van Dyck C. PBR28 Brain PET imaging with lipopolysaccharide challenge for the study of microglia function in Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.037792.
- Validation of a simplified tissue‐to‐reference ratio measurement using SUVR for the assessment of synaptic density alterations in Alzheimer’s disease using [11C]UCB‐J PETO'Dell R, Naganawa M, Toyonaga T, Young J, Dahal R, Singh E, Waheed A, Banks E, Harris J, Chen M, Nabulsi N, Huang Y, Carson R, van Dyck C, Mecca A. Validation of a simplified tissue‐to‐reference ratio measurement using SUVR for the assessment of synaptic density alterations in Alzheimer’s disease using [11C]UCB‐J PET. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.045928.
- In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimer’s diseaseMecca A, O'Dell R, Chen M, Naganawa M, Toyonaga T, Godek T, Harris J, Bartlett H, Zhao W, Gallezot J, Nabulsi N, Ropchan J, Ye Y, Wyk B, Arnsten A, Huang Y, Carson R, van Dyck C. In vivo measurement of widespread synaptic loss and associated tau accumulation in early Alzheimer’s disease. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.037791.
- PET Imaging of Synaptic Vesicle Protein 2AFinnema S, Li S, Cai Z, Naganawa M, Chen M, Matuskey D, Nabulsi N, Esterlis I, Holmes S, Radhakrishnan R, Toyonaga T, Huang Y, Carson R. PET Imaging of Synaptic Vesicle Protein 2A. 2020, 993-1019. DOI: 10.1007/978-3-030-53176-8_29.
- Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorderD’Souza D, Radhakrishnan R, Naganawa M, Ganesh S, Nabulsi N, Najafzadeh S, Ropchan J, Ranganathan M, Cortes-Briones J, Huang Y, Carson RE, Skosnik P. Preliminary in vivo evidence of lower hippocampal synaptic density in cannabis use disorder. Molecular Psychiatry 2020, 26: 3192-3200. PMID: 32973170, DOI: 10.1038/s41380-020-00891-4.
- Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11C]UCB‐J positron emission tomography studyFinnema SJ, Toyonaga T, Detyniecki K, Chen M, Dias M, Wang Q, Lin S, Naganawa M, Gallezot J, Lu Y, Nabulsi NB, Huang Y, Spencer DD, Carson RE. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [11C]UCB‐J positron emission tomography study. Epilepsia 2020, 61: 2183-2193. PMID: 32944949, DOI: 10.1111/epi.16653.
- Longitudinal imaging of metabotropic glutamate 5 receptors during early and extended alcohol abstinenceHillmer AT, Angarita GA, Esterlis I, Anderson JM, Nabulsi N, Lim K, Ropchan J, Carson RE, Krystal JH, Malley S, Cosgrove KP. Longitudinal imaging of metabotropic glutamate 5 receptors during early and extended alcohol abstinence. Neuropsychopharmacology 2020, 46: 380-385. PMID: 32919411, PMCID: PMC7852514, DOI: 10.1038/s41386-020-00856-9.
- First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET RadiotracerNaganawa M, Nabulsi N, Henry S, Matuskey D, Lin SF, Slieker L, Schwarz AJ, Kant N, Jesudason C, Ruley K, Navarro A, Gao H, Ropchan J, Labaree D, Carson RE, Huang Y. First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer. Journal Of Nuclear Medicine 2020, 62: 553-560. PMID: 32859711, PMCID: PMC8049371, DOI: 10.2967/jnumed.120.246967.
- First-in-Human Evaluation of 18F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2ANaganawa M, Li S, Nabulsi N, Henry S, Zheng MQ, Pracitto R, Cai Z, Gao H, Kapinos M, Labaree D, Matuskey D, Huang Y, Carson RE. First-in-Human Evaluation of 18F-SynVesT-1, a Radioligand for PET Imaging of Synaptic Vesicle Glycoprotein 2A. Journal Of Nuclear Medicine 2020, 62: 561-567. PMID: 32859701, PMCID: PMC8049363, DOI: 10.2967/jnumed.120.249144.
- Binding of the synaptic vesicle radiotracer [11C]UCB-J is unchanged during functional brain activation using a visual stimulation taskSmart K, Liu H, Matuskey D, Chen MK, Torres K, Nabulsi N, Labaree D, Ropchan J, Hillmer AT, Huang Y, Carson RE. Binding of the synaptic vesicle radiotracer [11C]UCB-J is unchanged during functional brain activation using a visual stimulation task. Cerebrovascular And Brain Metabolism Reviews 2020, 41: 1067-1079. PMID: 32757741, PMCID: PMC8054713, DOI: 10.1177/0271678x20946198.
- Human adult and adolescent biodistribution and dosimetry of the synaptic vesicle glycoprotein 2A radioligand 11C-UCB-JBini J, Holden D, Fontaine K, Mulnix T, Lu Y, Matuskey D, Ropchan J, Nabulsi N, Huang Y, Carson RE. Human adult and adolescent biodistribution and dosimetry of the synaptic vesicle glycoprotein 2A radioligand 11C-UCB-J. EJNMMI Research 2020, 10: 83. PMID: 32666239, PMCID: PMC7359974, DOI: 10.1186/s13550-020-00670-w.
- Simplified Quantification of 11C-UCB-J PET Evaluated in a Large Human CohortNaganawa M, Gallezot JD, Finnema SJ, Matuskey D, Mecca A, Nabulsi NB, Labaree D, Ropchan J, Malison RT, D'Souza DC, Esterlis I, Detyniecki K, van Dyck CH, Huang Y, Carson RE. Simplified Quantification of 11C-UCB-J PET Evaluated in a Large Human Cohort. Journal Of Nuclear Medicine 2020, 62: 418-421. PMID: 32646875, PMCID: PMC8049341, DOI: 10.2967/jnumed.120.243949.
- Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and cravingde Laat B, Nabulsi N, Huang Y, O’Malley S, Froehlich JC, Morris ED, Krishnan-Sarin S. Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving. Molecular Psychiatry 2020, 26: 5053-5060. PMID: 32541931, DOI: 10.1038/s41380-020-0811-8.
- In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PETMecca AP, Chen M, O'Dell RS, Naganawa M, Toyonaga T, Godek TA, Harris JE, Bartlett HH, Zhao W, Nabulsi NB, Wyk BCV, Varma P, Arnsten AFT, Huang Y, Carson RE, Dyck C. In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET. Alzheimer's & Dementia 2020, 16: 974-982. PMID: 32400950, PMCID: PMC7383876, DOI: 10.1002/alz.12097.
- PTSD is associated with neuroimmune suppression: evidence from PET imaging and postmortem transcriptomic studiesBhatt S, Hillmer AT, Girgenti MJ, Rusowicz A, Kapinos M, Nabulsi N, Huang Y, Matuskey D, Angarita GA, Esterlis I, Davis MT, Southwick SM, Friedman MJ, Duman R, Carson R, Krystal J, Pietrzak R, Cosgrove K. PTSD is associated with neuroimmune suppression: evidence from PET imaging and postmortem transcriptomic studies. Nature Communications 2020, 11: 2360. PMID: 32398677, PMCID: PMC7217830, DOI: 10.1038/s41467-020-15930-5.
- Inverse changes in raphe and cortical 5‐HT1B receptor availability after acute tryptophan depletion in healthy human subjectsBaldassarri SR, Park E, Finnema SJ, Planeta B, Nabulsi N, Najafzadeh S, Ropchan J, Huang Y, Hannestad J, Maloney K, Bhagwagar Z, Carson RE. Inverse changes in raphe and cortical 5‐HT1B receptor availability after acute tryptophan depletion in healthy human subjects. Synapse 2020, 74: e22159. PMID: 32324935, PMCID: PMC7426238, DOI: 10.1002/syn.22159.
- ASSOCIATION BETWEEN CEREBRAL AMYLOID ACCUMULATION AND SYNAPTIC DENSITY IN ALZHEIMER'S DISEASE: A MULTITRACER PET STUDYO'Dell R, Mecca A, Chen M, Godek T, Harris J, Bartlett H, Zhao W, Naganawa M, Toyonaga T, Lu Y, Nabulsi N, Wyk B, Varma P, Arnsten A, Huang Y, Carson R, van Dyck C. ASSOCIATION BETWEEN CEREBRAL AMYLOID ACCUMULATION AND SYNAPTIC DENSITY IN ALZHEIMER'S DISEASE: A MULTITRACER PET STUDY. American Journal Of Geriatric Psychiatry 2020, 28: s123-s124. DOI: 10.1016/j.jagp.2020.01.153.
- Separating dopamine D2 and D3 receptor sources of [11C]-(+)-PHNO binding potential: Independent component analysis of competitive bindingSmart K, Gallezot JD, Nabulsi N, Labaree D, Zheng MQ, Huang Y, Carson RE, Hillmer AT, Worhunsky PD. Separating dopamine D2 and D3 receptor sources of [11C]-(+)-PHNO binding potential: Independent component analysis of competitive binding. NeuroImage 2020, 214: 116762. PMID: 32201327, PMCID: PMC7263955, DOI: 10.1016/j.neuroimage.2020.116762.
- Kinetic Modeling and Test–Retest Reproducibility of 11C-EKAP and 11C-FEKAP, Novel Agonist Radiotracers for PET Imaging of the κ-Opioid Receptor in HumansNaganawa M, Li S, Nabulsi N, Lin SF, Labaree D, Ropchan J, Gao H, Mei M, Henry S, Matuskey D, Carson RE, Huang Y. Kinetic Modeling and Test–Retest Reproducibility of 11C-EKAP and 11C-FEKAP, Novel Agonist Radiotracers for PET Imaging of the κ-Opioid Receptor in Humans. Journal Of Nuclear Medicine 2020, 61: 1636-1642. PMID: 32169917, PMCID: PMC9364890, DOI: 10.2967/jnumed.119.227694.
- Body Mass Index and Age Effects on Brain 11β-Hydroxysteroid Dehydrogenase Type 1: a Positron Emission Tomography StudyBini J, Bhatt S, Hillmer AT, Gallezot JD, Nabulsi N, Pracitto R, Labaree D, Kapinos M, Ropchan J, Matuskey D, Sherwin RS, Jastreboff AM, Carson RE, Cosgrove K, Huang Y. Body Mass Index and Age Effects on Brain 11β-Hydroxysteroid Dehydrogenase Type 1: a Positron Emission Tomography Study. Molecular Imaging And Biology 2020, 22: 1124-1131. PMID: 32133575, PMCID: PMC7351613, DOI: 10.1007/s11307-020-01490-z.
- Synaptic Changes in Parkinson Disease Assessed with in vivo ImagingMatuskey D, Tinaz S, Wilcox KC, Naganawa M, Toyonaga T, Dias M, Henry S, Pittman B, Ropchan J, Nabulsi N, Suridjan I, Comley RA, Huang Y, Finnema SJ, Carson RE. Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging. Annals Of Neurology 2020, 87: 329-338. PMID: 31953875, PMCID: PMC7065227, DOI: 10.1002/ana.25682.
- Tobacco Smoking in People Is Not Associated with Altered 18-kDa Translocator Protein Levels: A PET StudyHillmer AT, Matuskey D, Huang Y, Nabulsi N, Ropchan J, Carson RE, O'Malley SS, Cosgrove KP. Tobacco Smoking in People Is Not Associated with Altered 18-kDa Translocator Protein Levels: A PET Study. Journal Of Nuclear Medicine 2020, 61: 1200-1204. PMID: 32005773, PMCID: PMC7413239, DOI: 10.2967/jnumed.119.237735.
- Synthesis and Preclinical Evaluation of an 18F‑Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [18F]SynVesT‑2Cai Z, Li S, Zhang W, Pracitto R, Wu X, Baum E, Finnema SJ, Holden D, Toyonaga T, Lin SF, Lindemann M, Shirali A, Labaree DC, Ropchan J, Nabulsi N, Carson RE, Huang Y. Synthesis and Preclinical Evaluation of an 18F‑Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [18F]SynVesT‑2. ACS Chemical Neuroscience 2020, 11: 592-603. PMID: 31961649, DOI: 10.1021/acschemneuro.9b00618.
- PET imaging of mGluR5 in Alzheimer’s diseaseMecca AP, McDonald JW, Michalak HR, Godek TA, Harris JE, Pugh EA, Kemp EC, Chen MK, Salardini A, Nabulsi NB, Lim K, Huang Y, Carson RE, Strittmatter SM, van Dyck CH. PET imaging of mGluR5 in Alzheimer’s disease. Alzheimer's Research & Therapy 2020, 12: 15. PMID: 31954399, PMCID: PMC6969979, DOI: 10.1186/s13195-020-0582-0.
- [11C]Methionine and [11C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation NecrosisTran TT, Gallezot JD, Jilaveanu LB, Zito C, Turcu G, Lim K, Nabulsi N, Huang H, Huttner A, Kluger HM, Chiang VL, Carson R. [11C]Methionine and [11C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis. Molecular Imaging 2020, 19: 1536012120968669. PMID: 33147119, PMCID: PMC7649862, DOI: 10.1177/1536012120968669.
- Measuring the effects of ketamine on mGluR5 using [18F]FPEB and PETHolmes SE, Gallezot JD, Davis MT, DellaGioia N, Matuskey D, Nabulsi N, Krystal JH, Javitch JA, DeLorenzo C, Carson RE, Esterlis I. Measuring the effects of ketamine on mGluR5 using [18F]FPEB and PET. Cerebrovascular And Brain Metabolism Reviews 2019, 40: 2254-2264. PMID: 31744389, PMCID: PMC7585925, DOI: 10.1177/0271678x19886316.
- In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PETRadhakrishnan R, Matuskey D, Nabulsi N, Gaiser E, Gallezot JD, Henry S, Planeta B, Lin SF, Ropchan J, Huang Y, Carson RE, D'Souza DC. In vivo 5-HT6 and 5-HT2A receptor availability in antipsychotic treated schizophrenia patients vs. unmedicated healthy humans measured with [11C]GSK215083 PET. Psychiatry Research Neuroimaging 2019, 295: 111007. PMID: 31760336, DOI: 10.1016/j.pscychresns.2019.111007.
- Binge alcohol use is not associated with alterations in striatal dopamine receptor binding or dopamine releaseWai JM, Grassetti A, Slifstein M, Matuskey D, Nabulsi N, Ropchan J, Labaree D, Huang Y, Martinez D. Binge alcohol use is not associated with alterations in striatal dopamine receptor binding or dopamine release. Drug And Alcohol Dependence 2019, 205: 107627. PMID: 31669800, PMCID: PMC6893096, DOI: 10.1016/j.drugalcdep.2019.107627.
- PET Imaging of Pancreatic Dopamine D2 and D3 Receptor Density with 11C-(+)-PHNO in Type 1 DiabetesBini J, Sanchez-Rangel E, Gallezot JD, Naganawa M, Nabulsi N, Lim K, Najafzadeh S, Shirali A, Ropchan J, Matuskey D, Huang Y, Herold K, Harris PE, Sherwin RS, Carson RE, Cline GW. PET Imaging of Pancreatic Dopamine D2 and D3 Receptor Density with 11C-(+)-PHNO in Type 1 Diabetes. Journal Of Nuclear Medicine 2019, 61: 570-576. PMID: 31601695, PMCID: PMC7198375, DOI: 10.2967/jnumed.119.234013.
- Assessment of a white matter reference region for 11C-UCB-J PET quantificationRossano S, Toyonaga T, Finnema SJ, Naganawa M, Lu Y, Nabulsi N, Ropchan J, De Bruyn S, Otoul C, Stockis A, Nicolas JM, Martin P, Mercier J, Huang Y, Maguire RP, Carson RE. Assessment of a white matter reference region for 11C-UCB-J PET quantification. Cerebrovascular And Brain Metabolism Reviews 2019, 40: 1890-1901. PMID: 31570041, PMCID: PMC7446568, DOI: 10.1177/0271678x19879230.
- Effects of age, BMI and sex on the glial cell marker TSPO — a multicentre [11C]PBR28 HRRT PET studyTuisku J, Plavén-Sigray P, Gaiser EC, Airas L, Al-Abdulrasul H, Brück A, Carson RE, Chen MK, Cosgrove KP, Ekblad L, Esterlis I, Farde L, Forsberg A, Halldin C, Helin S, Kosek E, Lekander M, Lindgren N, Marjamäki P, Rissanen E, Sucksdorff M, Varrone A, Collste K, Gallezot J, Hillmer A, Huang Y, Höglund C, Johansson J, Jucaite A, Lampa J, Nabulsi N, Pittman B, Sandiego C, Stenkrona P, Rinne J, Matuskey D, Cervenka S. Effects of age, BMI and sex on the glial cell marker TSPO — a multicentre [11C]PBR28 HRRT PET study. European Journal Of Nuclear Medicine And Molecular Imaging 2019, 46: 2329-2338. PMID: 31363804, PMCID: PMC6717599, DOI: 10.1007/s00259-019-04403-7.
- Sex differences in amphetamine-induced dopamine release in the dorsolateral prefrontal cortex of tobacco smokersZakiniaeiz Y, Hillmer AT, Matuskey D, Nabulsi N, Ropchan J, Mazure CM, Picciotto MR, Huang Y, McKee SA, Morris ED, Cosgrove KP. Sex differences in amphetamine-induced dopamine release in the dorsolateral prefrontal cortex of tobacco smokers. Neuropsychopharmacology 2019, 44: 2205-2211. PMID: 31269510, PMCID: PMC6897943, DOI: 10.1038/s41386-019-0456-y.
- P2‐349: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTI‐TRACER STUDY OF HEALTHY AGING AND ALZHEIMER'S DISEASEMecca A, Chen M, Godek T, Harris J, Bartlett H, Toyonaga T, Naganawa M, Salardini A, Arnsten A, Nabulsi N, Lim K, Najafzadeh S, Ropchan J, Huang Y, Carson R, Strittmatter S, van Dyck C. P2‐349: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTI‐TRACER STUDY OF HEALTHY AGING AND ALZHEIMER'S DISEASE. Alzheimer's & Dementia 2019, 15: p729-p729. DOI: 10.1016/j.jalz.2019.06.2756.
- IC‐P‐140: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTI‐TRACER STUDY IN HEALTHY AGING AND ALZHEIMER'S DISEASEMecca A, Chen M, Godek T, Harris J, Bartlett H, Toyonaga T, Naganawa M, Salardini A, Arnsten A, Nabulsi N, Lim K, Najafzadeh S, Ropchan J, Huang Y, Carson R, Strittmatter S, Dyck C. IC‐P‐140: ASSOCIATION BETWEEN MGLUR5 AND SYNAPTIC DENSITY: A MULTI‐TRACER STUDY IN HEALTHY AGING AND ALZHEIMER'S DISEASE. Alzheimer's & Dementia 2019, 15: p115-p115. DOI: 10.1016/j.jalz.2019.06.4254.
- P4‐481: ASSOCIATION BETWEEN ENTORHINAL CORTICAL TAU ACCUMULATION AND HIPPOCAMPAL SYNAPTIC DENSITY IN OLDER INDIVIDUALS WITH NORMAL COGNITION AND EARLY ALZHEIMER'S DISEASE: PRELIMINARY EXPERIENCEMecca A, Chen M, Naganawa M, Toyonaga T, Godek T, Harris J, Bartlett H, Gallezot J, Charil A, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C. P4‐481: ASSOCIATION BETWEEN ENTORHINAL CORTICAL TAU ACCUMULATION AND HIPPOCAMPAL SYNAPTIC DENSITY IN OLDER INDIVIDUALS WITH NORMAL COGNITION AND EARLY ALZHEIMER'S DISEASE: PRELIMINARY EXPERIENCE. Alzheimer's & Dementia 2019, 15: p1497-p1497. DOI: 10.1016/j.jalz.2019.08.027.
- The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Cravingde Laat B, Goldberg A, Shi J, Tetrault JM, Nabulsi N, Zheng MQ, Najafzadeh S, Gao H, Kapinos M, Ropchan J, O'Malley SS, Huang Y, Morris ED, Krishnan-Sarin S. The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. Biological Psychiatry 2019, 86: 864-871. PMID: 31399255, DOI: 10.1016/j.biopsych.2019.05.021.
- Synthesis and in vivo evaluation of [18F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A)Li S, Cai Z, Zhang W, Holden D, Lin SF, Finnema SJ, Shirali A, Ropchan J, Carre S, Mercier J, Carson RE, Nabulsi N, Huang Y. Synthesis and in vivo evaluation of [18F]UCB-J for PET imaging of synaptic vesicle glycoprotein 2A (SV2A). European Journal Of Nuclear Medicine And Molecular Imaging 2019, 46: 1952-1965. PMID: 31175396, PMCID: PMC6810698, DOI: 10.1007/s00259-019-04357-w.
- In vivo evidence for dysregulation of mGluR5 as a biomarker of suicidal ideationDavis MT, Hillmer A, Holmes SE, Pietrzak RH, DellaGioia N, Nabulsi N, Matuskey D, Angarita G, Carson RE, Krystal JH, Esterlis I. In vivo evidence for dysregulation of mGluR5 as a biomarker of suicidal ideation. Proceedings Of The National Academy Of Sciences Of The United States Of America 2019, 116: 11490-11495. PMID: 31085640, PMCID: PMC6561298, DOI: 10.1073/pnas.1818871116.
- 142. Synaptic Density Alterations are Associated With Depression Severity and Network AlterationsHolmes S, Scheinost D, Finnema S, Naganawa M, Davis M, DellaGioia N, Nabulsi N, Matuskey D, Angarita G, Pietrzak R, Duman R, Sanacora G, Krystal J, Carson R, Esterlis I. 142. Synaptic Density Alterations are Associated With Depression Severity and Network Alterations. Biological Psychiatry 2019, 85: s59. DOI: 10.1016/j.biopsych.2019.03.156.
- Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography studyMartinez D, Slifstein M, Matuskey D, Nabulsi N, Zheng MQ, Lin SF, Ropchan J, Urban N, Grassetti A, Chang D, Salling M, Foltin R, Carson RE, Huang Y. Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography study. Neuropsychopharmacology 2019, 44: 1720-1727. PMID: 31026862, PMCID: PMC6785004, DOI: 10.1038/s41386-019-0398-4.
- S13. IN VIVO EVIDENCE OF REDUCED SYNAPTIC VESICLE DENSITY IN SCHIZOPHRENIA USING [11C] UCB-J PET IMAGINGRadhakrishnan R, Skosnik P, Ranganathan M, Naganawa M, Finnema S, Esterlis I, Huang Y, Nabulsi N, Carson R, D’Souza D. S13. IN VIVO EVIDENCE OF REDUCED SYNAPTIC VESICLE DENSITY IN SCHIZOPHRENIA USING [11C] UCB-J PET IMAGING. Schizophrenia Bulletin 2019, 45: s310-s311. PMCID: PMC6455499, DOI: 10.1093/schbul/sbz020.558.
- Lower synaptic density is associated with depression severity and network alterationsHolmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, Sanacora G, Krystal JH, Carson RE, Esterlis I. Lower synaptic density is associated with depression severity and network alterations. Nature Communications 2019, 10: 1529. PMID: 30948709, PMCID: PMC6449365, DOI: 10.1038/s41467-019-09562-7.
- Social status and demographic effects of the kappa opioid receptor: a PET imaging study with a novel agonist radiotracer in healthy volunteersMatuskey D, Dias M, Naganawa M, Pittman B, Henry S, Li S, Gao H, Ropchan J, Nabulsi N, Carson RE, Huang Y. Social status and demographic effects of the kappa opioid receptor: a PET imaging study with a novel agonist radiotracer in healthy volunteers. Neuropsychopharmacology 2019, 44: 1714-1719. PMID: 30928993, PMCID: PMC6785144, DOI: 10.1038/s41386-019-0379-7.
- A single‐center, open‐label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteersFinnema SJ, Rossano S, Naganawa M, Henry S, Gao H, Pracitto R, Maguire RP, Mercier J, Kervyn S, Nicolas J, Klitgaard H, DeBruyn S, Otoul C, Martin P, Muglia P, Matuskey D, Nabulsi NB, Huang Y, Kaminski RM, Hannestad J, Stockis A, Carson RE. A single‐center, open‐label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. Epilepsia 2019, 60: 958-967. PMID: 30924924, PMCID: PMC6532410, DOI: 10.1111/epi.14701.
- First in-human PET study and kinetic evaluation of [18F]AS2471907 for imaging 11β-hydroxysteroid dehydrogenase type 1Bhatt S, Nabulsi NB, Li S, Cai Z, Matuskey D, Bini J, Najafzadeh S, Kapinos M, Ropchan JR, Carson RE, Cosgrove KP, Huang Y, Hillmer AT. First in-human PET study and kinetic evaluation of [18F]AS2471907 for imaging 11β-hydroxysteroid dehydrogenase type 1. Cerebrovascular And Brain Metabolism Reviews 2019, 40: 695-704. PMID: 30895878, PMCID: PMC7168798, DOI: 10.1177/0271678x19838633.
- Imaging the Enzyme 11β-Hydroxysteroid Dehydrogenase Type 1 with PET: Evaluation of the Novel Radiotracer 11C-AS2471907 in Human BrainGallezot JD, Nabulsi N, Henry S, Pracitto R, Planeta B, Ropchan J, Lin SF, Labaree D, Kapinos M, Shirali A, Lara-Jaime T, Gao H, Matuskey D, Walzer M, Marek GJ, Bellaire S, Yuan N, Carson RE, Huang Y. Imaging the Enzyme 11β-Hydroxysteroid Dehydrogenase Type 1 with PET: Evaluation of the Novel Radiotracer 11C-AS2471907 in Human Brain. Journal Of Nuclear Medicine 2019, 60: 1140-1146. PMID: 30877174, DOI: 10.2967/jnumed.118.219766.
- Evaluation of 11C-LSN3172176 as a Novel PET Tracer for Imaging M1 Muscarinic Acetylcholine Receptors in Nonhuman PrimatesNabulsi NB, Holden D, Zheng MQ, Bois F, Lin SF, Najafzadeh S, Gao H, Ropchan J, Lara-Jaime T, Labaree D, Shirali A, Slieker L, Jesudason C, Barth V, Navarro A, Kant N, Carson RE, Huang Y. Evaluation of 11C-LSN3172176 as a Novel PET Tracer for Imaging M1 Muscarinic Acetylcholine Receptors in Nonhuman Primates. Journal Of Nuclear Medicine 2019, 60: 1147-1153. PMID: 30733324, DOI: 10.2967/jnumed.118.222034.
- Quantification of Positron Emission Tomography Data Using Simultaneous Estimation of the Input Function: Validation with Venous Blood and Replication of Clinical StudiesBartlett EA, Ananth M, Rossano S, Zhang M, Yang J, Lin SF, Nabulsi N, Huang Y, Zanderigo F, Parsey RV, DeLorenzo C. Quantification of Positron Emission Tomography Data Using Simultaneous Estimation of the Input Function: Validation with Venous Blood and Replication of Clinical Studies. Molecular Imaging And Biology 2018, 21: 926-934. PMID: 30535672, PMCID: PMC6555699, DOI: 10.1007/s11307-018-1300-1.
- Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman PrimatesLi S, Cai Z, Wu X, Holden D, Pracitto R, Kapinos M, Gao H, Labaree D, Nabulsi N, Carson RE, Huang Y. Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates. ACS Chemical Neuroscience 2018, 10: 1544-1554. PMID: 30396272, PMCID: PMC6810685, DOI: 10.1021/acschemneuro.8b00526.
- Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic ImagingChen MK, Mecca AP, Naganawa M, Finnema SJ, Toyonaga T, Lin SF, Najafzadeh S, Ropchan J, Lu Y, McDonald JW, Michalak HR, Nabulsi NB, Arnsten AFT, Huang Y, Carson RE, van Dyck CH. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. JAMA Neurology 2018, 75: 1215-1224. PMID: 30014145, PMCID: PMC6233853, DOI: 10.1001/jamaneurol.2018.1836.
- PET imaging reveals lower kappa opioid receptor availability in alcoholics but no effect of ageVijay A, Cavallo D, Goldberg A, de Laat B, Nabulsi N, Huang Y, Krishnan-Sarin S, Morris ED. PET imaging reveals lower kappa opioid receptor availability in alcoholics but no effect of age. Neuropsychopharmacology 2018, 43: 2539-2547. PMID: 30188515, PMCID: PMC6224533, DOI: 10.1038/s41386-018-0199-1.
- PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseasesCai Z, Li S, Matuskey D, Nabulsi N, Huang Y. PET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases. Neuroscience Letters 2018, 691: 44-50. PMID: 30075287, PMCID: PMC6339829, DOI: 10.1016/j.neulet.2018.07.038.
- Kappa opioid receptor binding in major depression: A pilot studyMiller JM, Zanderigo F, Purushothaman PD, DeLorenzo C, Rubin‐Falcone H, Ogden RT, Keilp J, Oquendo MA, Nabulsi N, Huang YH, Parsey RV, Carson RE, Mann JJ. Kappa opioid receptor binding in major depression: A pilot study. Synapse 2018, 72: e22042. PMID: 29935119, PMCID: PMC7599086, DOI: 10.1002/syn.22042.
- IC‐P‐183: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCEMecca A, Chen M, Naganawa M, Finnema S, Toyonaga T, Lin S, Gallezot J, McDonald J, Michalak H, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C. IC‐P‐183: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. Alzheimer's & Dementia 2018, 14: p152-p153. DOI: 10.1016/j.jalz.2018.06.2250.
- P2‐365: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCEChen M, Mecca A, Naganawa M, Finnema S, Toyonaga T, Gallezot J, McDonald J, Michalak H, Nabulsi N, Huang Y, Arnsten A, Carson R, Dyck C. P2‐365: PET IMAGING OF SYNAPTIC DENSITY (SYNAPTIC VESICLE GLYCOPROTEIN 2A, SV2A) IN ALZHEIMER'S DISEASE: INITIAL EXPERIENCE. Alzheimer's & Dementia 2018, 14: p832-p832. DOI: 10.1016/j.jalz.2018.06.1056.
- P1‐469: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASEMecca A, McDonald J, Michalak H, Godek T, Harris J, Chen M, Nabulsi N, Salardini A, Carson R, Strittmatter S, van Dyck C. P1‐469: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. Alzheimer's & Dementia 2018, 14: p501-p503. DOI: 10.1016/j.jalz.2018.06.479.
- Novel Use of Agent 11C-PHNO for Pet CT Imaging of Pancreatic Beta-Cell MassRANGEL E, BINI J, NABULSI N, HUANG Y, HEROLD K, SHERWIN R, CARSON R, CLINE G. Novel Use of Agent 11C-PHNO for Pet CT Imaging of Pancreatic Beta-Cell Mass. Diabetes 2018, 67 DOI: 10.2337/db18-2145-p.
- IC‐04‐03: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASEMecca A, McDonald J, Michalak H, Godek T, Harris J, Chen M, Nabulsi N, Salardini A, Carson R, Strittmatter S, van Dyck C. IC‐04‐03: PET IMAGING OF METABOTROPIC GLUTAMATE RECEPTOR 5 BINDING IN ALZHEIMER'S DISEASE. Alzheimer's & Dementia 2018, 14: p8-p9. DOI: 10.1016/j.jalz.2018.06.2051.
- 2181 Age-related change in 5-HT6 receptor availability in healthy male volunteers measured with 11C-GSK215083 PETRadhakrishnan R, Nabulsi N, Gaiser E, Gallezot J, Henry S, Planeta B, Lin S, Ropchan J, Williams W, Morris E, D’Souza D, Huang Y, Carson R, Matuskey D. 2181 Age-related change in 5-HT6 receptor availability in healthy male volunteers measured with 11C-GSK215083 PET. Journal Of Clinical And Translational Science 2018, 2: 3-4. PMCID: PMC6799074, DOI: 10.1017/cts.2018.44.
- F149. Preliminary Evidence for Altered Synaptic Density and a Possible Role for Accelerated Ageing in Individuals With MDD as Measured With [11C]UCB-J PETHolmes S, Finnema S, Davis M, DellaGioia N, Naganawa M, Nabulsi N, Matuskey D, Pietrzak R, Duman R, Sanacora G, Carson R, Esterlis I. F149. Preliminary Evidence for Altered Synaptic Density and a Possible Role for Accelerated Ageing in Individuals With MDD as Measured With [11C]UCB-J PET. Biological Psychiatry 2018, 83: s296. DOI: 10.1016/j.biopsych.2018.02.763.
- F188. Preliminary Evidence for mGluR5 Dysregulation in Borderline Personality Disorder and Relationship to Suicidal BehaviorDavis M, Holmes S, DellaGioia N, O'Grady S, Axelrod S, Nabulsi N, Matuskey D, Carson R, Esterlis I. F188. Preliminary Evidence for mGluR5 Dysregulation in Borderline Personality Disorder and Relationship to Suicidal Behavior. Biological Psychiatry 2018, 83: s312. DOI: 10.1016/j.biopsych.2018.02.802.
- Age-Related Change in 5-HT6 Receptor Availability in Healthy Male Volunteers Measured with 11C-GSK215083 PETRadhakrishnan R, Nabulsi N, Gaiser E, Gallezot JD, Henry S, Planeta B, Lin SF, Ropchan J, Williams W, Morris E, D'Souza DC, Huang Y, Carson RE, Matuskey D. Age-Related Change in 5-HT6 Receptor Availability in Healthy Male Volunteers Measured with 11C-GSK215083 PET. Journal Of Nuclear Medicine 2018, 59: 1445-1450. PMID: 29626125, PMCID: PMC6126437, DOI: 10.2967/jnumed.117.206516.
- Poster Number: NR 14 Initial Experience with PET Imaging of Synaptic Density (SV2A) in Alzheimer's Disease: A New Biomarker for Clinical Trials?Mecca A, Chen M, Naganawa M, Finnema S, Toyonaga T, Lin S, McDonald J, Michalak H, Nabulsi N, Huang Y, Arnsten A, Carson R, van Dyck C. Poster Number: NR 14 Initial Experience with PET Imaging of Synaptic Density (SV2A) in Alzheimer's Disease: A New Biomarker for Clinical Trials? American Journal Of Geriatric Psychiatry 2018, 26: s145-s146. DOI: 10.1016/j.jagp.2018.01.176.
- Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [18F]FP-DTBZ in Healthy Subjects and Patients with Type 1 DiabetesNaganawa M, Lim K, Nabulsi NB, Lin SF, Labaree D, Ropchan J, Herold KC, Huang Y, Harris P, Ichise M, Cline GW, Carson RE. Evaluation of Pancreatic VMAT2 Binding with Active and Inactive Enantiomers of [18F]FP-DTBZ in Healthy Subjects and Patients with Type 1 Diabetes. Molecular Imaging And Biology 2018, 20: 835-845. PMID: 29468404, PMCID: PMC6533199, DOI: 10.1007/s11307-018-1170-6.
- Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia SubjectsD’Souza D, Carson RE, Driesen N, Johannesen J, Ranganathan M, Krystal JH, Ahn K, Bielen K, Carbuto M, Deaso E, D’Souza D, Ranganathan M, Naganawa M, Ranganathan M, D’Souza D, Nabulsi N, Zheng M, Lin S, Huang Y, Carson R, Driesen N, Ahn K, Morgan P, Suckow R, He G, McCarthy G, Krystal J, Johannesen J, Kenney J, Gelernter J, Gueorguieva R, Pittman B. Dose-Related Target Occupancy and Effects on Circuitry, Behavior, and Neuroplasticity of the Glycine Transporter-1 Inhibitor PF-03463275 in Healthy and Schizophrenia Subjects. Biological Psychiatry 2018, 84: 413-421. PMID: 29499855, PMCID: PMC6068006, DOI: 10.1016/j.biopsych.2017.12.019.
- Evaluation of PET Brain Radioligands for Imaging Pancreatic β-Cell Mass: Potential Utility of 11C-(+)-PHNOBini J, Naganawa M, Nabulsi N, Huang Y, Ropchan J, Lim K, Najafzadeh S, Herold KC, Cline GW, Carson RE. Evaluation of PET Brain Radioligands for Imaging Pancreatic β-Cell Mass: Potential Utility of 11C-(+)-PHNO. Journal Of Nuclear Medicine 2018, 59: 1249-1254. PMID: 29371405, PMCID: PMC6071501, DOI: 10.2967/jnumed.117.197285.
- Evaluation of (‐)‐[18F]Flubatine‐specific binding: Implications for reference region approachesBhatt S, Hillmer AT, Nabulsi N, Matuskey D, Lim K, Lin S, Esterlis I, Carson RE, Huang Y, Cosgrove KP. Evaluation of (‐)‐[18F]Flubatine‐specific binding: Implications for reference region approaches. Synapse 2017, 72 PMID: 29105121, PMCID: PMC6547815, DOI: 10.1002/syn.22016.
- Cortical β-amyloid burden, gray matter, and memory in adults at varying APOE ε4 risk for Alzheimer's diseaseMecca AP, Barcelos NM, Wang S, Brück A, Nabulsi N, Planeta-Wilson B, Nadelmann J, Benincasa AL, Ropchan J, Huang Y, Gelernter J, Van Ness PH, Carson RE, van Dyck CH. Cortical β-amyloid burden, gray matter, and memory in adults at varying APOE ε4 risk for Alzheimer's disease. Neurobiology Of Aging 2017, 61: 207-214. PMID: 29111487, PMCID: PMC5722236, DOI: 10.1016/j.neurobiolaging.2017.09.027.
- The Effect of Treatment with Guanfacine, an Alpha2 Adrenergic Agonist, on Dopaminergic Tone in Tobacco Smokers: An [11C]FLB457 PET StudySandiego CM, Matuskey D, Lavery M, McGovern E, Huang Y, Nabulsi N, Ropchan J, Picciotto MR, Morris ED, McKee SA, Cosgrove KP. The Effect of Treatment with Guanfacine, an Alpha2 Adrenergic Agonist, on Dopaminergic Tone in Tobacco Smokers: An [11C]FLB457 PET Study. Neuropsychopharmacology 2017, 43: 1052-1058. PMID: 28944773, PMCID: PMC5854798, DOI: 10.1038/npp.2017.223.
- A modification to improve the reliability of [11C]CN− production in the GE radiochemistry systemLabaree DC, Ropchan JR, Nabulsi N, Huang Y. A modification to improve the reliability of [11C]CN− production in the GE radiochemistry system. Journal Of Labelled Compounds And Radiopharmaceuticals 2017, 60: 592-595. PMID: 28833348, DOI: 10.1002/jlcr.3540.
- Evaluation of the Lysophosphatidic Acid Receptor Type 1 Radioligand 11C-BMT-136088 for Lung Imaging in Rhesus MonkeysGallezot JD, Nabulsi NB, Holden D, Lin SF, Labaree D, Ropchan J, Najafzadeh S, Donnelly DJ, Cao K, Bonacorsi S, Seiders J, Roppe J, Hayes W, Huang Y, Du S, Carson RE. Evaluation of the Lysophosphatidic Acid Receptor Type 1 Radioligand 11C-BMT-136088 for Lung Imaging in Rhesus Monkeys. Journal Of Nuclear Medicine 2017, 59: 327-333. PMID: 28864634, DOI: 10.2967/jnumed.117.195073.
- Kinetic evaluation and test–retest reproducibility of [11C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humansFinnema SJ, Nabulsi NB, Mercier J, Lin SF, Chen MK, Matuskey D, Gallezot JD, Henry S, Hannestad J, Huang Y, Carson RE. Kinetic evaluation and test–retest reproducibility of [11C]UCB-J, a novel radioligand for positron emission tomography imaging of synaptic vesicle glycoprotein 2A in humans. Cerebrovascular And Brain Metabolism Reviews 2017, 38: 2041-2052. PMID: 28792356, PMCID: PMC6259313, DOI: 10.1177/0271678x17724947.
- Microglial depletion and activation: A [11C]PBR28 PET study in nonhuman primatesHillmer AT, Holden D, Fowles K, Nabulsi N, West BL, Carson RE, Cosgrove KP. Microglial depletion and activation: A [11C]PBR28 PET study in nonhuman primates. EJNMMI Research 2017, 7: 59. PMID: 28741281, PMCID: PMC5524658, DOI: 10.1186/s13550-017-0305-0.
- Altered metabotropic glutamate receptor 5 markers in PTSD: In vivo and postmortem evidenceHolmes SE, Girgenti MJ, Davis MT, Pietrzak RH, DellaGioia N, Nabulsi N, Matuskey D, Southwick S, Duman RS, Carson RE, Krystal JH, Esterlis I, Friedman M, Kowall N, Brady C, McKee A, Stein T, Huber B, Kaloupek D, Alvarez V, Benedek D, Ursano R, Williamson D, Cruz D, Young K, Duman R, Krystal J, Mash D, Hardegree M, Serlin G. Altered metabotropic glutamate receptor 5 markers in PTSD: In vivo and postmortem evidence. Proceedings Of The National Academy Of Sciences Of The United States Of America 2017, 114: 8390-8395. PMID: 28716937, PMCID: PMC5547601, DOI: 10.1073/pnas.1701749114.
- 18 In Vivo Quantification of mGluR5 Availability in Posttraumatic Stress DisorderDavis M, Holmes S, Pietrzak R, DellaGioia N, Nabulsi N, Matuskey D, Southwick S, Carson R, Krystal J, Esterlis I. 18 In Vivo Quantification of mGluR5 Availability in Posttraumatic Stress Disorder. Biological Psychiatry 2017, 81: s8. DOI: 10.1016/j.biopsych.2017.02.029.
- 962 In-vivo Evidence of Decreased Synaptic Density in Schizophrenia: A [11C]UCB-J PET Imaging StudyRadhakrishnan R, Skosnik P, Finnema S, Rotolo R, Forselius-Bielen K, Creatura G, Nabulsi N, Carson R, D׳Souza D. 962 In-vivo Evidence of Decreased Synaptic Density in Schizophrenia: A [11C]UCB-J PET Imaging Study. Biological Psychiatry 2017, 81: s389. DOI: 10.1016/j.biopsych.2017.02.688.
- Use of Electronic Cigarettes Leads to Significant Beta2-Nicotinic Acetylcholine Receptor Occupancy: Evidence From a PET Imaging StudyBaldassarri SR, Hillmer AT, Anderson JM, Jatlow P, Nabulsi N, Labaree D, Cosgrove KP, O’Malley S, Eissenberg T, Krishnan-Sarin S, Esterlis I. Use of Electronic Cigarettes Leads to Significant Beta2-Nicotinic Acetylcholine Receptor Occupancy: Evidence From a PET Imaging Study. Nicotine & Tobacco Research 2017, 20: 425-433. PMID: 28460123, PMCID: PMC5896427, DOI: 10.1093/ntr/ntx091.
- Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depressionEsterlis I, DellaGioia N, Pietrzak RH, Matuskey D, Nabulsi N, Abdallah CG, Yang J, Pittenger C, Sanacora G, Krystal JH, Parsey RV, Carson RE, DeLorenzo C. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression. Molecular Psychiatry 2017, 23: 824-832. PMID: 28397841, PMCID: PMC5636649, DOI: 10.1038/mp.2017.58.
- Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging StudyAbdallah CG, Hannestad J, Mason GF, Holmes SE, DellaGioia N, Sanacora G, Jiang L, Matuskey D, Satodiya R, Gasparini F, Lin X, Javitch J, Planeta B, Nabulsi N, Carson RE, Esterlis I. Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2017, 2: 449-456. PMID: 28993818, PMCID: PMC5630181, DOI: 10.1016/j.bpsc.2017.03.019.
- Systemic inflammation enhances stimulant-induced striatal dopamine elevationPetrulli J, Kalish B, Nabulsi N, Huang Y, Hannestad J, Morris E. Systemic inflammation enhances stimulant-induced striatal dopamine elevation. Translational Psychiatry 2017, 7: e1076-e1076. PMID: 28350401, PMCID: PMC5404612, DOI: 10.1038/tp.2017.18.
- Poster Number: EI 39 Investigating Age Related Associations of Metabotropic Glutamate Receptor 5 Density Using [18F]FPEB and PETMecca A, Rogers K, Jacobs Z, McDonald J, Michalak H, DellaGioia N, Nabulsi N, Matuskey D, Esterlis I, Carson R, van Dyck C. Poster Number: EI 39 Investigating Age Related Associations of Metabotropic Glutamate Receptor 5 Density Using [18F]FPEB and PET. American Journal Of Geriatric Psychiatry 2017, 25: s96-s97. DOI: 10.1016/j.jagp.2017.01.110.
- Regional and network-based alterations in D2/D3 receptor availability in cocaine use disorderWorhunsky P, Matuskey D, Gallezot J, Nabulsi N, Angarita G, Calhoun V, Malison R, Potenza M, Carson R. Regional and network-based alterations in D2/D3 receptor availability in cocaine use disorder. Drug And Alcohol Dependence 2017, 171: e219. DOI: 10.1016/j.drugalcdep.2016.08.598.
- PET imaging of α7 nicotinic acetylcholine receptors: a comparative study of [18F]ASEM and [18F]DBT-10 in nonhuman primates, and further evaluation of [18F]ASEM in humansHillmer AT, Li S, Zheng MQ, Scheunemann M, Lin SF, Nabulsi N, Holden D, Pracitto R, Labaree D, Ropchan J, Teodoro R, Deuther-Conrad W, Esterlis I, Cosgrove KP, Brust P, Carson RE, Huang Y. PET imaging of α7 nicotinic acetylcholine receptors: a comparative study of [18F]ASEM and [18F]DBT-10 in nonhuman primates, and further evaluation of [18F]ASEM in humans. European Journal Of Nuclear Medicine And Molecular Imaging 2017, 44: 1042-1050. PMID: 28120003, PMCID: PMC5400702, DOI: 10.1007/s00259-017-3621-8.
- Regional and source-based patterns of [11C]-(+)-PHNO binding potential reveal concurrent alterations in dopamine D2 and D3 receptor availability in cocaine-use disorderWorhunsky PD, Matuskey D, Gallezot JD, Gaiser EC, Nabulsi N, Angarita GA, Calhoun VD, Malison RT, Potenza MN, Carson RE. Regional and source-based patterns of [11C]-(+)-PHNO binding potential reveal concurrent alterations in dopamine D2 and D3 receptor availability in cocaine-use disorder. NeuroImage 2017, 148: 343-351. PMID: 28110088, PMCID: PMC5344702, DOI: 10.1016/j.neuroimage.2017.01.045.
- A multi species evaluation of the radiation dosimetry of [11C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitorPetrulli JR, Hansen SB, Abourbeh G, Yaqub M, Bahce I, Holden D, Huang Y, Nabulsi NB, Contessa JN, Mishani E, Lammertsma AA, Morris ED. A multi species evaluation of the radiation dosimetry of [11C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor. Nuclear Medicine And Biology 2017, 47: 56-61. PMID: 28126682, PMCID: PMC5360653, DOI: 10.1016/j.nucmedbio.2016.12.009.
- The Search for a Subtype-Selective PET Imaging Agent for the GABAA Receptor Complex: Evaluation of the Radiotracer [11C]ADO in Nonhuman PrimatesLin SF, Bois F, Holden D, Nabulsi N, Pracitto R, Gao H, Kapinos M, Teng JK, Shirali A, Ropchan J, Carson RE, Elmore CS, Vasdev N, Huang Y. The Search for a Subtype-Selective PET Imaging Agent for the GABAA Receptor Complex: Evaluation of the Radiotracer [11C]ADO in Nonhuman Primates. Molecular Imaging 2017, 16: 1536012117731258. PMID: 28929924, PMCID: PMC5912275, DOI: 10.1177/1536012117731258.
- PET imaging reveals sex differences in kappa opioid receptor availability in humans, in vivo.Vijay A, Wang S, Worhunsky P, Zheng MQ, Nabulsi N, Ropchan J, Krishnan-Sarin S, Huang Y, Morris ED. PET imaging reveals sex differences in kappa opioid receptor availability in humans, in vivo. Am J Nucl Med Mol Imaging 2016, 6: 205-14. PMID: 27648372, PMCID: PMC5004062.
- Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNOGirgis RR, Slifstein M, D’Souza D, Lee Y, Periclou A, Ghahramani P, Laszlovszky I, Durgam S, Adham N, Nabulsi N, Huang Y, Carson RE, Kiss B, Kapás M, Abi-Dargham A, Rakhit A. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. Psychopharmacology 2016, 233: 3503-3512. PMID: 27525990, PMCID: PMC5035321, DOI: 10.1007/s00213-016-4382-y.
- Quantification of myocardial blood flow with 82Rb: Validation with 15O-water using time-of-flight and point-spread-function modelingGermino M, Ropchan J, Mulnix T, Fontaine K, Nabulsi N, Ackah E, Feringa H, Sinusas AJ, Liu C, Carson RE. Quantification of myocardial blood flow with 82Rb: Validation with 15O-water using time-of-flight and point-spread-function modeling. EJNMMI Research 2016, 6: 68. PMID: 27650280, PMCID: PMC5030203, DOI: 10.1186/s13550-016-0215-6.
- Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746Gallezot JD, Planeta B, Nabulsi N, Palumbo D, Li X, Liu J, Rowinski C, Chidsey K, Labaree D, Ropchan J, Lin SF, Sawant-Basak A, McCarthy TJ, Schmidt AW, Huang Y, Carson RE. Determination of receptor occupancy in the presence of mass dose: [11C]GSK189254 PET imaging of histamine H3 receptor occupancy by PF-03654746. Cerebrovascular And Brain Metabolism Reviews 2016, 37: 1095-1107. PMID: 27207170, PMCID: PMC5363483, DOI: 10.1177/0271678x16650697.
- Imaging synaptic density in the living human brainFinnema SJ, Nabulsi NB, Eid T, Detyniecki K, Lin SF, Chen MK, Dhaher R, Matuskey D, Baum E, Holden D, Spencer DD, Mercier J, Hannestad J, Huang Y, Carson RE. Imaging synaptic density in the living human brain. Science Translational Medicine 2016, 8: 348ra96. PMID: 27440727, DOI: 10.1126/scitranslmed.aaf6667.
- Imaging of cerebral α4β2* nicotinic acetylcholine receptors with (−)-[18F]Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brainHillmer AT, Esterlis I, Gallezot JD, Bois F, Zheng MQ, Nabulsi N, Lin SF, Papke RL, Huang Y, Sabri O, Carson RE, Cosgrove KP. Imaging of cerebral α4β2* nicotinic acetylcholine receptors with (−)-[18F]Flubatine PET: Implementation of bolus plus constant infusion and sensitivity to acetylcholine in human brain. NeuroImage 2016, 141: 71-80. PMID: 27426839, PMCID: PMC5026941, DOI: 10.1016/j.neuroimage.2016.07.026.
- Quantitative projection of human brain penetration of the H3 antagonist PF-03654746 by integrating rat-derived brain partitioning and PET receptor occupancySawant-Basak A, Chen L, Shaffer CL, Palumbo D, Schmidt A, Tseng E, Spracklin DK, Gallezot JD, Labaree D, Nabulsi N, Huang Y, Carson RE, McCarthy T. Quantitative projection of human brain penetration of the H3 antagonist PF-03654746 by integrating rat-derived brain partitioning and PET receptor occupancy. Xenobiotica 2016, 47: 119-126. PMID: 27353353, DOI: 10.3109/00498254.2016.1166531.
- Preclinical Evaluation of 18F-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A EnzymeChen L, Nabulsi N, Naganawa M, Zasadny K, Skaddan MB, Zhang L, Najafzadeh S, Lin SF, Helal CJ, Boyden TL, Chang C, Ropchan J, Carson RE, Villalobos A, Huang Y. Preclinical Evaluation of 18F-PF-05270430, a Novel PET Radioligand for the Phosphodiesterase 2A Enzyme. Journal Of Nuclear Medicine 2016, 57: 1448-1453. PMID: 27199356, PMCID: PMC5093921, DOI: 10.2967/jnumed.115.171454.
- First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430Naganawa M, Waterhouse RN, Nabulsi N, Lin SF, Labaree D, Ropchan J, Tarabar S, DeMartinis N, Ogden A, Banerjee A, Huang Y, Carson RE. First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430. Journal Of Nuclear Medicine 2016, 57: 1388-1395. PMID: 27103022, PMCID: PMC5093918, DOI: 10.2967/jnumed.115.166850.
- Age-related changes in binding of the D2/3 receptor radioligand [11C](+)PHNO in healthy volunteersMatuskey D, Worhunksy P, Correa E, Pittman B, Gallezot JD, Nabulsi N, Ropchan J, Sreeram V, Gudepu R, Gaiser E, Cosgrove K, Ding YS, Potenza MN, Huang Y, Malison RT, Carson RE. Age-related changes in binding of the D2/3 receptor radioligand [11C](+)PHNO in healthy volunteers. NeuroImage 2016, 130: 241-247. PMID: 26876475, PMCID: PMC4808424, DOI: 10.1016/j.neuroimage.2016.02.002.
- OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor bindingPittenger C, Adams TG, Gallezot JD, Crowley MJ, Nabulsi N, Ropchan J, Gao H, Kichuk SA, Simpson R, Billingslea E, Hannestad J, Bloch M, Mayes L, Bhagwagar Z, Carson RE. OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor binding. Journal Of Affective Disorders 2016, 196: 87-96. PMID: 26919057, PMCID: PMC4808438, DOI: 10.1016/j.jad.2016.02.021.
- Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the BrainNabulsi N, Mercier J, Holden D, Carré S, Najafzadeh S, Vandergeten MC, Lin SF, Deo A, Price N, Wood M, Lara-Jaime T, Montel F, Laruelle M, Carson RE, Hannestad J, Huang Y. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain. Journal Of Nuclear Medicine 2016, 57: 777-784. PMID: 26848175, DOI: 10.2967/jnumed.115.168179.
- In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEBDeLorenzo C, Gallezot JD, Gardus J, Yang J, Planeta B, Nabulsi N, Ogden RT, Labaree DC, Huang YH, Mann JJ, Gasparini F, Lin X, Javitch JA, Parsey RV, Carson RE, Esterlis I. In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB. Cerebrovascular And Brain Metabolism Reviews 2016, 37: 2716-2727. PMID: 27742888, PMCID: PMC5536783, DOI: 10.1177/0271678x16673646.
- Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of actionNicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, Huang Y, Chanteux H, Staelens L, Matagne A, Mathy FX, Mercier J, Stockis A, Carson RE, Klitgaard H. Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia 2015, 57: 201-209. PMID: 26663401, DOI: 10.1111/epi.13267.
- Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050Naganawa M, Dickinson GL, Zheng MQ, Henry S, Vandenhende F, Witcher J, Bell R, Nabulsi N, Lin SF, Ropchan J, Neumeister A, Ranganathan M, Tauscher J, Huang Y, Carson RE. Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050. Journal Of Pharmacology And Experimental Therapeutics 2015, 356: 260-266. PMID: 26628406, PMCID: PMC4727157, DOI: 10.1124/jpet.115.229278.
- Imaging robust microglial activation after lipopolysaccharide administration in humans with PETSandiego CM, Gallezot JD, Pittman B, Nabulsi N, Lim K, Lin SF, Matuskey D, Lee JY, O’Connor K, Huang Y, Carson RE, Hannestad J, Cosgrove KP. Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. Proceedings Of The National Academy Of Sciences Of The United States Of America 2015, 112: 12468-12473. PMID: 26385967, PMCID: PMC4603509, DOI: 10.1073/pnas.1511003112.
- A preliminary study of dopamine D2/3 receptor availability and social status in healthy and cocaine dependent humans imaged with [11C](+)PHNOMatuskey D, Gaiser EC, Gallezot JD, Angarita GA, Pittman B, Nabulsi N, Ropchan J, MaCleod P, Cosgrove KP, Ding YS, Potenza MN, Carson RE, Malison RT. A preliminary study of dopamine D2/3 receptor availability and social status in healthy and cocaine dependent humans imaged with [11C](+)PHNO. Drug And Alcohol Dependence 2015, 154: 167-173. PMID: 26164205, PMCID: PMC4536182, DOI: 10.1016/j.drugalcdep.2015.06.039.
- Brivaracetam (BRV) Achieves Brain SV2A Occupancy Faster than Levetiracetam (LEV) (S22.003)Mercier J, Holden D, Deo A, Fowles K, Kervyn S, Nabulsi N, Nicolas J, Klitgaard H, Huang Y, D'Souza J, Carson R, Hannestad J. Brivaracetam (BRV) Achieves Brain SV2A Occupancy Faster than Levetiracetam (LEV) (S22.003). Neurology 2015, 84 DOI: 10.1212/wnl.84.14_supplement.s22.003.
- Deficits in Prefrontal Cortical and Extrastriatal Dopamine Release in Schizophrenia: A Positron Emission Tomographic Functional Magnetic Resonance Imaging StudySlifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, Hackett E, Girgis R, Ojeil N, Moore H, D’Souza D, Malison RT, Huang Y, Lim K, Nabulsi N, Carson RE, Lieberman JA, Abi-Dargham A. Deficits in Prefrontal Cortical and Extrastriatal Dopamine Release in Schizophrenia: A Positron Emission Tomographic Functional Magnetic Resonance Imaging Study. JAMA Psychiatry 2015, 72: 316-324. PMID: 25651194, PMCID: PMC4768742, DOI: 10.1001/jamapsychiatry.2014.2414.
- Imaging human brown adipose tissue under room temperature conditions with 11C-MRB, a selective norepinephrine transporter PET ligandHwang JJ, Yeckel CW, Gallezot JD, Aguiar RB, Ersahin D, Gao H, Kapinos M, Nabulsi N, Huang Y, Cheng D, Carson RE, Sherwin R, Ding YS. Imaging human brown adipose tissue under room temperature conditions with 11C-MRB, a selective norepinephrine transporter PET ligand. Metabolism 2015, 64: 747-755. PMID: 25798999, PMCID: PMC4408242, DOI: 10.1016/j.metabol.2015.03.001.
- Test–Retest Reproducibility of Binding Parameters in Humans with 11C-LY2795050, an Antagonist PET Radiotracer for the κ Opioid ReceptorNaganawa M, Zheng MQ, Henry S, Nabulsi N, Lin SF, Ropchan J, Labaree D, Najafzadeh S, Kapinos M, Tauscher J, Neumeister A, Carson RE, Huang Y. Test–Retest Reproducibility of Binding Parameters in Humans with 11C-LY2795050, an Antagonist PET Radiotracer for the κ Opioid Receptor. Journal Of Nuclear Medicine 2015, 56: 243-248. PMID: 25593119, PMCID: PMC4322754, DOI: 10.2967/jnumed.114.147975.
- Sex Differences in the Brain's Dopamine Signature of Cigarette SmokingCosgrove KP, Wang S, Kim SJ, McGovern E, Nabulsi N, Gao H, Labaree D, Tagare HD, Sullivan JM, Morris ED. Sex Differences in the Brain's Dopamine Signature of Cigarette Smoking. Journal Of Neuroscience 2014, 34: 16851-16855. PMID: 25505336, PMCID: PMC4261105, DOI: 10.1523/jneurosci.3661-14.2014.
- S.08.04 Imaging glutamate homeostasis in cocaine addictionMartinez D, Slifstein M, Nabulsi N, Grassetti A, Urban N, Perez A, Liu F, Lin S, Ropchan J, Mao X, Kegeles L, Shungu D, Carson R, Huang Y. S.08.04 Imaging glutamate homeostasis in cocaine addiction. European Neuropsychopharmacology 2014, 24: s122. DOI: 10.1016/s0924-977x(14)70151-8.
- Kinetic Modeling of 11C-LY2795050, A Novel Antagonist Radiotracer for PET Imaging of the Kappa Opioid Receptor in HumansNaganawa M, Zheng MQ, Nabulsi N, Tomasi G, Henry S, Lin SF, Ropchan J, Labaree D, Tauscher J, Neumeister A, Carson RE, Huang Y. Kinetic Modeling of 11C-LY2795050, A Novel Antagonist Radiotracer for PET Imaging of the Kappa Opioid Receptor in Humans. Cerebrovascular And Brain Metabolism Reviews 2014, 34: 1818-1825. PMID: 25182664, PMCID: PMC4269759, DOI: 10.1038/jcbfm.2014.150.
- In Vivo Ketamine-Induced Changes in [11C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5DeLorenzo C, DellaGioia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C, Yang J, Wen R, Mann JJ, Krystal JH, Parsey RV, Carson RE, Esterlis I. In Vivo Ketamine-Induced Changes in [11C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5. Biological Psychiatry 2014, 77: 266-275. PMID: 25156701, PMCID: PMC4277907, DOI: 10.1016/j.biopsych.2014.06.024.
- Evaluation of the agonist PET radioligand [11C]GR103545 to image kappa opioid receptor in humans: Kinetic model selection, test–retest reproducibility and receptor occupancy by the antagonist PF-04455242Naganawa M, Jacobsen LK, Zheng MQ, Lin SF, Banerjee A, Byon W, Weinzimmer D, Tomasi G, Nabulsi N, Grimwood S, Badura LL, Carson RE, McCarthy TJ, Huang Y. Evaluation of the agonist PET radioligand [11C]GR103545 to image kappa opioid receptor in humans: Kinetic model selection, test–retest reproducibility and receptor occupancy by the antagonist PF-04455242. NeuroImage 2014, 99: 69-79. PMID: 24844744, PMCID: PMC4140089, DOI: 10.1016/j.neuroimage.2014.05.033.
- Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 Binding Sites in Rhesus BrainParker CA, Nabulsi N, Holden D, Lin SF, Cass T, Labaree D, Kealey S, Gee AD, Husbands SM, Quelch D, Carson RE, Nutt DJ, Huang Y, Tyacke RJ. Evaluation of 11C-BU99008, a PET Ligand for the Imidazoline2 Binding Sites in Rhesus Brain. Journal Of Nuclear Medicine 2014, 55: 838-844. PMID: 24711648, DOI: 10.2967/jnumed.113.131854.
- Phosphodiesterase 10A PET Radioligand Development Program: From Pig to HumanPlisson C, Weinzimmer D, Jakobsen S, Natesan S, Salinas C, Lin SF, Labaree D, Zheng MQ, Nabulsi N, Marques TR, Kapur S, Kawanishi E, Saijo T, Gunn RN, Carson RE, Rabiner EA. Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human. Journal Of Nuclear Medicine 2014, 55: 595-601. PMID: 24614221, DOI: 10.2967/jnumed.113.131409.
- Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[11C]O-methylreboxetineLi CS, Potenza MN, Lee DE, Planeta B, Gallezot JD, Labaree D, Henry S, Nabulsi N, Sinha R, Ding YS, Carson RE, Neumeister A. Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[11C]O-methylreboxetine. NeuroImage 2013, 86: 306-310. PMID: 24121204, PMCID: PMC3947246, DOI: 10.1016/j.neuroimage.2013.10.004.
- Imaging Glutamate Homeostasis in Cocaine Addiction with the Metabotropic Glutamate Receptor 5 Positron Emission Tomography Radiotracer [11C]ABP688 and Magnetic Resonance SpectroscopyMartinez D, Slifstein M, Nabulsi N, Grassetti A, Urban NB, Perez A, Liu F, Lin SF, Ropchan J, Mao X, Kegeles LS, Shungu DC, Carson RE, Huang Y. Imaging Glutamate Homeostasis in Cocaine Addiction with the Metabotropic Glutamate Receptor 5 Positron Emission Tomography Radiotracer [11C]ABP688 and Magnetic Resonance Spectroscopy. Biological Psychiatry 2013, 75: 165-171. PMID: 24035345, PMCID: PMC4106018, DOI: 10.1016/j.biopsych.2013.06.026.
- Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHDDing YS, Naganawa M, Gallezot JD, Nabulsi N, Lin SF, Ropchan J, Weinzimmer D, McCarthy TJ, Carson RE, Huang Y, Laruelle M. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD. NeuroImage 2013, 86: 164-171. PMID: 23933039, DOI: 10.1016/j.neuroimage.2013.08.001.
- Tracer Kinetic Modeling of [11C]AFM, a New PET Imaging Agent for the Serotonin TransporterNaganawa M, Nabulsi N, Planeta B, Gallezot JD, Lin SF, Najafzadeh S, Williams W, Ropchan J, Labaree D, Neumeister A, Huang Y, Carson RE. Tracer Kinetic Modeling of [11C]AFM, a New PET Imaging Agent for the Serotonin Transporter. Cerebrovascular And Brain Metabolism Reviews 2013, 33: 1886-1896. PMID: 23921898, PMCID: PMC3851894, DOI: 10.1038/jcbfm.2013.134.
- Determination of the In Vivo Selectivity of a New κ-Opioid Receptor Antagonist PET Tracer 11C-LY2795050 in the Rhesus MonkeyKim SJ, Zheng MQ, Nabulsi N, Labaree D, Ropchan J, Najafzadeh S, Carson RE, Huang Y, Morris ED. Determination of the In Vivo Selectivity of a New κ-Opioid Receptor Antagonist PET Tracer 11C-LY2795050 in the Rhesus Monkey. Journal Of Nuclear Medicine 2013, 54: 1668-1674. PMID: 23918735, PMCID: PMC5824998, DOI: 10.2967/jnumed.112.118877.
- The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A [11C]PBR28 PET studyHannestad J, DellaGioia N, Gallezot JD, Lim K, Nabulsi N, Esterlis I, Pittman B, Lee JY, O’Connor K, Pelletier D, Carson RE. The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A [11C]PBR28 PET study. Brain Behavior And Immunity 2013, 33: 131-138. PMID: 23850810, PMCID: PMC3899398, DOI: 10.1016/j.bbi.2013.06.010.
- Studies of the metabotropic glutamate receptor 5 radioligand [11C]ABP688 with N‐acetylcysteine challenge in rhesus monkeysSandiego CM, Nabulsi N, Lin S, Labaree D, Najafzadeh S, Huang Y, Cosgrove K, Carson RE. Studies of the metabotropic glutamate receptor 5 radioligand [11C]ABP688 with N‐acetylcysteine challenge in rhesus monkeys. Synapse 2013, 67: 489-501. PMID: 23424090, PMCID: PMC3710146, DOI: 10.1002/syn.21656.
- Determination of In Vivo Bmax and Kd for 11C-GR103545, an Agonist PET Tracer for κ-Opioid Receptors: A Study in Nonhuman PrimatesTomasi G, Nabulsi N, Zheng MQ, Weinzimmer D, Ropchan J, Blumberg L, Brown-Proctor C, Ding YS, Carson RE, Huang Y. Determination of In Vivo Bmax and Kd for 11C-GR103545, an Agonist PET Tracer for κ-Opioid Receptors: A Study in Nonhuman Primates. Journal Of Nuclear Medicine 2013, 54: 600-608. PMID: 23424192, PMCID: PMC3775350, DOI: 10.2967/jnumed.112.112672.
- Synthesis and Evaluation of 11C-LY2795050 as a κ-Opioid Receptor Antagonist Radiotracer for PET ImagingZheng MQ, Nabulsi N, Kim SJ, Tomasi G, Lin SF, Mitch C, Quimby S, Barth V, Rash K, Masters J, Navarro A, Seest E, Morris ED, Carson RE, Huang Y. Synthesis and Evaluation of 11C-LY2795050 as a κ-Opioid Receptor Antagonist Radiotracer for PET Imaging. Journal Of Nuclear Medicine 2013, 54: 455-463. PMID: 23353688, PMCID: PMC3775344, DOI: 10.2967/jnumed.112.109512.
- Age Effects on Serotonin Receptor 1B as Assessed by PETMatuskey D, Pittman B, Planeta-Wilson B, Walderhaug E, Henry S, Gallezot JD, Nabulsi N, Ding YS, Bhagwagar Z, Malison R, Carson RE, Neumeister A. Age Effects on Serotonin Receptor 1B as Assessed by PET. Journal Of Nuclear Medicine 2012, 53: 1411-1414. PMID: 22851636, PMCID: PMC3690814, DOI: 10.2967/jnumed.112.103598.
- Affinity and selectivity of [11C]‐(+)‐PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivoGallezot J, Beaver JD, Gunn RN, Nabulsi N, Weinzimmer D, Singhal T, Slifstein M, Fowles K, Ding Y, Huang Y, Laruelle M, Carson RE, Rabiner EA. Affinity and selectivity of [11C]‐(+)‐PHNO for the D3 and D2 receptors in the rhesus monkey brain in vivo. Synapse 2012, 66: 489-500. PMID: 22213512, DOI: 10.1002/syn.21535.
- The Effect of Early Trauma Exposure on Serotonin Type 1B Receptor Expression Revealed by Reduced Selective Radioligand BindingMurrough JW, Czermak C, Henry S, Nabulsi N, Gallezot JD, Gueorguieva R, Planeta-Wilson B, Krystal JH, Neumaier JF, Huang Y, Ding YS, Carson RE, Neumeister A. The Effect of Early Trauma Exposure on Serotonin Type 1B Receptor Expression Revealed by Reduced Selective Radioligand Binding. JAMA Psychiatry 2011, 68: 892-900. PMID: 21893657, PMCID: PMC3244836, DOI: 10.1001/archgenpsychiatry.2011.91.
- P4‐253: Receptor occupancy of the 5‐HT6 receptor antagonist SAM‐760 in non‐human primates and healthy human volunteersComery T, Zasadny K, Morris E, Antinew J, Bell J, Billing B, Boyden T, Esterlis I, Huang Y, Kupiec J, Kuszpit K, Leil T, Nabulsi N, Planeta‐Wilson B, Plotka A, Skaddan M, Vandal G, Carson R, Katz E, McCarthy T. P4‐253: Receptor occupancy of the 5‐HT6 receptor antagonist SAM‐760 in non‐human primates and healthy human volunteers. Alzheimer's & Dementia 2011, 7: s794-s795. DOI: 10.1016/j.jalz.2011.05.2278.
- Assessing the sensitivity of [11C]p943, a novel 5‐HTIB radioligand, to endogenous serotonin releaseCosgrove KP, Kloczynski T, Nabulsi N, Weinzimmer D, Lin S, Staley JK, Bhagwagar Z, Carson RE. Assessing the sensitivity of [11C]p943, a novel 5‐HTIB radioligand, to endogenous serotonin release. Synapse 2011, 65: 1113-1117. PMID: 21484884, PMCID: PMC3149753, DOI: 10.1002/syn.20942.
- [11C]GR103545: novel one-pot radiosynthesis with high specific activityNabulsi NB, Zheng MQ, Ropchan J, Labaree D, Ding YS, Blumberg L, Huang Y. [11C]GR103545: novel one-pot radiosynthesis with high specific activity. Nuclear Medicine And Biology 2010, 38: 215-221. PMID: 21315277, DOI: 10.1016/j.nucmedbio.2010.08.014.
- Evaluation of [11C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primatesGallezot JD, Weinzimmer D, Nabulsi N, Lin SF, Fowles K, Sandiego C, McCarthy TJ, Maguire RP, Carson RE, Ding YS. Evaluation of [11C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates. NeuroImage 2010, 56: 268-279. PMID: 20869448, PMCID: PMC3710586, DOI: 10.1016/j.neuroimage.2010.09.040.
- Pancreatic Beta Cell Mass PET Imaging and Quantification with [11C]DTBZ and [18F]FP-(+)-DTBZ in Rodent Models of DiabetesSinghal T, Ding YS, Weinzimmer D, Normandin MD, Labaree D, Ropchan J, Nabulsi N, Lin SF, Skaddan MB, Soeller WC, Huang Y, Carson RE, Treadway JL, Cline GW. Pancreatic Beta Cell Mass PET Imaging and Quantification with [11C]DTBZ and [18F]FP-(+)-DTBZ in Rodent Models of Diabetes. Molecular Imaging And Biology 2010, 13: 973-984. PMID: 20824509, PMCID: PMC3711476, DOI: 10.1007/s11307-010-0406-x.
- Kinetic analysis of the kappa agonist tracer [11C]GR103545 in healthy controlsTomasi G, Zheng M, Ropchan J, Weinzimmer D, Linn S, Nabulsi N, Williams W, Ding Y, Jacobsen L, Huang H, Carson R. Kinetic analysis of the kappa agonist tracer [11C]GR103545 in healthy controls. NeuroImage 2010, 52: s172. DOI: 10.1016/j.neuroimage.2010.04.140.
- A correction algorithm for carryover of tracer in paired C-11 studies: Application to the H-3 receptor antagonist [C-11]GSK189254Planeta-Wilson B, Labaree D, Gallezot J, Lin S, Nabulsi N, Williams W, McCarthy T, Ding Y, Huang Y, Carson R. A correction algorithm for carryover of tracer in paired C-11 studies: Application to the H-3 receptor antagonist [C-11]GSK189254. NeuroImage 2010, 52: s166. DOI: 10.1016/j.neuroimage.2010.04.135.
- Synthesis and evaluation of [C-11]LY2795050, an antagonist PET imaging tracer for the kappa opioid receptorsZheng M, Nabulsi N, Tomasi G, Mitch C, Quimby S, Barth V, Rash K, Masters J, Navarro A, Seest E, Carson R, Huang Y. Synthesis and evaluation of [C-11]LY2795050, an antagonist PET imaging tracer for the kappa opioid receptors. NeuroImage 2010, 52: s120. DOI: 10.1016/j.neuroimage.2010.04.098.
- Medical devices with broad spectrum antimicrobial activity.United States Patent 7,651,661, Jan 26, 2010. (https://www.google.com.au/patents/US7651661)
- Antiseptic derivatives with broad spectrum antimicrobial activity for the impregnation of surfaces.United States Patent 7,713,472. (http://www.google.com/patents/US7713472)
- High-resolution imaging of brain 5-HT1B receptors in the rhesus monkey using [11C]P943Nabulsi N, Huang Y, Weinzimmer D, Ropchan J, Frost JJ, McCarthy T, Carson RE, Ding YS. High-resolution imaging of brain 5-HT1B receptors in the rhesus monkey using [11C]P943. Nuclear Medicine And Biology 2009, 37: 205-214. PMID: 20152720, PMCID: PMC3780362, DOI: 10.1016/j.nucmedbio.2009.10.007.
- Kinetic Modeling of the Serotonin 5-HT1B Receptor Radioligand [11C]P943 in HumansGallezot JD, Nabulsi N, Neumeister A, Planeta-Wilson B, Williams WA, Singhal T, Kim S, Maguire RP, McCarthy T, Frost JJ, Huang Y, Ding YS, Carson RE. Kinetic Modeling of the Serotonin 5-HT1B Receptor Radioligand [11C]P943 in Humans. Cerebrovascular And Brain Metabolism Reviews 2009, 30: 196-210. PMID: 19773803, PMCID: PMC2949107, DOI: 10.1038/jcbfm.2009.195.
- PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)‐[11C]O‐methylreboxetine and HRRTDing Y, Singhal T, Planeta‐Wilson B, Gallezot J, Nabulsi N, Labaree D, Ropchan J, Henry S, Williams W, Carson RE, Neumeister A, Malison RT. PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)‐[11C]O‐methylreboxetine and HRRT. Synapse 2009, 64: 30-38. PMID: 19728366, PMCID: PMC3727644, DOI: 10.1002/syn.20696.
- Dopamine D3 receptor antagonists: The quest for a potentially selective PET ligand. Part 3: Radiosynthesis and in vivo studiesBennacef I, Salinas CA, Bonasera TA, Gunn RN, Audrain H, Jakobsen S, Nabulsi N, Weinzimmer D, Carson RE, Huang Y, Holmes I, Micheli F, Heidbreder C, Gentile G, Rossi T, Laruelle M. Dopamine D3 receptor antagonists: The quest for a potentially selective PET ligand. Part 3: Radiosynthesis and in vivo studies. Bioorganic & Medicinal Chemistry Letters 2009, 19: 5056-5059. PMID: 19635669, DOI: 10.1016/j.bmcl.2009.07.055.
- In vivo Scatchard analysis of bolus/infusion 5-HT1B studies with [11C]P943: Comparison between SRTM and equilibrium methodsTomasi G, Nabulsi N, Weinzimmer D, Sandiego C, Gallezot J, Wang E, McLean S, Huang Y, Ding Y, Carson R. In vivo Scatchard analysis of bolus/infusion 5-HT1B studies with [11C]P943: Comparison between SRTM and equilibrium methods. NeuroImage 2008, 41: t16. DOI: 10.1016/j.neuroimage.2008.04.190.
- PET imaging of norepinephrine transporter in cocaine abuser using (S,S)-[11C]MRBSinghal T, Planeta-Wilson B, Gallezot J, Henry S, Nabulsi N, Labaree D, Ropchan J, Carson R, Neumeister A, Malison R, Ding Y. PET imaging of norepinephrine transporter in cocaine abuser using (S,S)-[11C]MRB. NeuroImage 2008, 41: t195. DOI: 10.1016/j.neuroimage.2008.04.162.
- Quantification of serotonin transporters with [11C]AFM: Evaluation of reference region methodsNaganawa M, Planeta-Wilson B, Nabulsi N, Ropchan J, Labaree D, Neumeister A, Huang Y, Carson R. Quantification of serotonin transporters with [11C]AFM: Evaluation of reference region methods. NeuroImage 2008, 41: t28. DOI: 10.1016/j.neuroimage.2008.04.202.
- First in human evaluation of [11C]AFM, a novel PET tracer for the serotonin transporterWilliams W, Neumeister A, Nabulsi N, Ropchan J, Labaree D, Planeta-Wilson B, Najafzadeh S, Carson R, Huang Y. First in human evaluation of [11C]AFM, a novel PET tracer for the serotonin transporter. NeuroImage 2008, 41: t42. DOI: 10.1016/j.neuroimage.2008.04.216.
- PET Imaging of serotonin transporter as a biomarker for axon damage and regeneration in spinal cord injuryHuang Y, Nabulsi N, Weinzimmer D, Fung E, Ropchan J, Labaree D, Wang X, Gould G, Frost J, Carson R, Strittmatter S. PET Imaging of serotonin transporter as a biomarker for axon damage and regeneration in spinal cord injury. NeuroImage 2008, 41: t154. DOI: 10.1016/j.neuroimage.2008.04.122.
- Evaluation of [11C]MRB for receptor occupancy studies of norepinephrine transportersGallezot J, Weinzimmer D, Nabulsi N, Lin S, Fowles K, Maguire P, Carson R, Ding Y. Evaluation of [11C]MRB for receptor occupancy studies of norepinephrine transporters. NeuroImage 2008, 41: t49. DOI: 10.1016/j.neuroimage.2008.04.223.
- Serotonin-1B receptor imaging in PTSDNeumeister A, Czermak C, Henry S, Planeta-Wilson B, Huang H, Ding Y, Krystal J, Nabulsi N, Gallezot J, Carson R. Serotonin-1B receptor imaging in PTSD. NeuroImage 2008, 41: t163. DOI: 10.1016/j.neuroimage.2008.04.130.
- [11C]Glycylsarcosine: synthesis and in vivo evaluation as a PET tracer of PepT2 transporter function in kidney of PepT2 null and wild-type miceNabulsi NB, Smith DE, Kilbourn MR. [11C]Glycylsarcosine: synthesis and in vivo evaluation as a PET tracer of PepT2 transporter function in kidney of PepT2 null and wild-type mice. Bioorganic & Medicinal Chemistry 2005, 13: 2993-3001. PMID: 15781409, DOI: 10.1016/j.bmc.2005.02.002.
- TARGETING PEPT1 FOR DETECTING PANCREAS CANCER WITH [11C]GLY-SAR: MICROPET IMAGING OF NUDE MICE BEARING ASPC-1, CAPAN-2, and MPANC-96 XENOGRAFTS.Journal of Labelled Compounds and Radiopharmaceuticals. Vol 48, Issue S1, Page S58. Abstract. (http://onlinelibrary.wiley.com/doi/10.1002/jlcr.978/epdf)
Clinical Trials
Conditions | Study Title |
---|---|
Diseases of the Nervous System | Meditation and Synaptic Density |
Diseases of the Nervous System | Study of Safety and of the Mechanism of BLZ945 in ALS Patients |
Mental Health & Behavioral Research | HPA axis function in the brains of PTSD, Trauma Exposed, or Otherwise Healthy research participants utilizing PET and MRI imaging |
Addictive Behaviors | PET Imaging of Microglia with [11C]PBR28 in Opioid Dependent and Healthy Control Subjects |
Child Development & Autism | PET Imaging Study for Young Adults with ASD |
Diseases of the Nervous System | Imaging the Dopamine Transporter in Parkinson's Disease |
Diseases of the Nervous System | Imaging pancreatic beta-cells with PET neuroimaging agent 11C-PHNO |
Diseases of the Nervous System; Mental Health & Behavioral Research | SV2A PET Imaging in Healthy Subjects and Epilepsy Patients |
Obesity & Weight Control | Imaging cortisol metabolism in liver, adipose tissue and brain with a novel PET radioligand |